0000816956-22-000004 | 10-K | XBRL Viewer

Print Document View Excel Document

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
ASSETS
Cash and cash equivalents	$ 20,847	$ 27,356
Accounts receivable, less allowance for doubtful accounts of $4,528 in 2021 and $3,876 in 2020	183,882	177,152
Inventories	231,644	194,868
Prepaid expenses and other current assets	23,750	17,278
Total current assets	460,123	416,654
Property, plant and equipment, net	108,863	111,407
Deferred income taxes	9,657	6,842
Goodwill	617,528	618,440
Other intangible assets, net	471,049	501,537
Other assets	98,797	96,793
Total assets	1,766,017	1,751,673
LIABILITIES AND SHAREHOLDERS' EQUITY
Current portion of long-term debt	12,249	18,415
Accounts payable	58,197	53,310
Accrued compensation and benefits	60,488	50,171
Other current liabilities	65,712	68,305
Total current liabilities	196,646	190,201
Long-term debt	672,407	735,221
Deferred income taxes	68,537	57,875
Other long-term liabilities	42,992	59,338
Total liabilities	980,582	1,042,635
Commitments and contingencies
Preferred stock, par value $.01 per share; authorized 500,000 shares, none issued or outstanding	0	0
Common stock, par value $.01 per share; 100,000,000 authorized; 31,299,194 issued in 2021 and 2020, respectively	313	313
Paid-in capital	396,771	382,628
Retained earnings	496,605	457,417
Accumulated other comprehensive loss	(54,203)	(63,681)
Less: Treasury stock, at cost; 1,925,893 and 2,410,045 shares in 2021 and 2020, respectively	(54,051)	(67,639)
Total shareholders' equity	785,435	709,038
Total liabilities and shareholders' equity	$ 1,766,017	$ 1,751,673

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 4,528	$ 3,876
Preferred stock, par value (in dollars per per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	500,000	500,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	31,299,194	31,299,194
Treasury stock, shares (in shares)	1,925,893	2,410,045

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Revenues	$ 1,010,635	$ 862,459	$ 955,097
Cost of sales	442,599	402,159	430,382
Gross profit	568,036	460,300	524,715
Selling and administrative expense	414,754	373,817	400,141
Research and development expense	43,565	40,473	45,460
Total operating expenses	458,319	414,290	445,601
Income from operations	109,717	46,010	79,114
Interest expense	35,485	44,052	42,701
Other expense	1,127	355	5,188
Income before income taxes	73,105	1,603	31,225
Provision (benefit) for income taxes	10,563	(7,914)	2,605
Net income	$ 62,542	$ 9,517	$ 28,620
Earnings per share:
Basic (in dollars per share)	$ 2.14	$ 0.33	$ 1.01
Diluted (in dollars per share)	$ 1.94	$ 0.32	$ 0.97
Other comprehensive income (loss), before income tax:
Cash flow hedging	$ 12,660	$ (8,489)	$ (4,736)
Pension liability	9,163	(6,499)	35
Foreign currency translation adjustments	(7,072)	6,963	25
Other comprehensive income (loss), before income tax	14,751	(8,025)	(4,676)
Provision (benefit) for income taxes related to items in other comprehensive income	5,273	(3,621)	(1,136)
Other Comprehensive Income (Loss), Net of Income Tax	9,478	(4,404)	(3,540)
Comprehensive income	$ 72,020	$ 5,113	$ 25,080

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Loss [Member]	Treasury Stock [Member]
Balance at period start (shares) at Dec. 31, 2018		31,299
Balance at period start at Dec. 31, 2018	$ 662,270	$ 313	$ 341,738	$ 464,851	$ (55,737)	$ (88,895)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans	4,315		(3,843)			8,158
Stock-based compensation	11,779		11,779
Dividends on common stock ($.80 per share)	(22,627)			(22,627)
Convertible notes discount, net	39,145		39,145
Convertible notes debt issuance costs	(1,233)		(1,233)
Convertible notes hedge, net	(38,829)		(38,829)
Issuance of warrants	30,567		30,567
Comprehensive income (loss):
Cash flow hedging gain (loss) (net of income tax expense/benefit)					(3,592)
Pension liability (net of income tax expense/benefit)					27
Foreign currency translation adjustments					25
Net income	28,620			28,620
Comprehensive income	25,080
Balance at period end (shares) at Dec. 31, 2019		31,299
Balance at period end at Dec. 31, 2019	710,467	$ 313	379,324	470,844	(59,277)	(80,737)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans	3,291		(9,807)			13,098
Stock-based compensation	13,111		13,111
Dividends on common stock ($.80 per share)	(22,944)			(22,944)
Comprehensive income (loss):
Cash flow hedging gain (loss) (net of income tax expense/benefit)					(6,438)
Pension liability (net of income tax expense/benefit)					(4,929)
Foreign currency translation adjustments					6,963
Net income	9,517			9,517
Comprehensive income	5,113
Balance at period end (shares) at Dec. 31, 2020		31,299
Balance at period end at Dec. 31, 2020	709,038	$ 313	382,628	457,417	(63,681)	(67,639)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans	11,396		(2,192)			13,588
Stock-based compensation	16,335		16,335
Dividends on common stock ($.80 per share)	(23,354)			(23,354)
Comprehensive income (loss):
Cash flow hedging gain (loss) (net of income tax expense/benefit)					9,601
Pension liability (net of income tax expense/benefit)					6,949
Foreign currency translation adjustments					(7,072)
Net income	62,542			62,542
Comprehensive income	72,020
Balance at period end (shares) at Dec. 31, 2021		31,299
Balance at period end at Dec. 31, 2021	$ 785,435	$ 313	$ 396,771	$ 496,605	$ (54,203)	$ (54,051)

Consolidated Statements of Shareholder's Equity (Parenthetical) - $ / shares			12 Months Ended
	Oct. 28, 2013	Feb. 29, 2012	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Shareholders' Equity Parenthetical [Abstract]
Dividends per share of common stock (in dollars per share)	$ 0.20	$ 0.15	$ 0.80	$ 0.80	$ 0.80

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net income	$ 62,542	$ 9,517	$ 28,620
Adjustments to reconcile net income to net cash provided by operating acitivites:
Depreciation	16,494	18,044	18,688
Amortization of Debt Discount	10,217	9,692	8,302
Amortization of Deferred Debt Issuance Costs	3,726	3,723	3,454
Amortization	54,249	54,581	53,635
Stock-based compensation	16,335	13,111	11,779
Impairment charges	0	0	312
Deferred income taxes	3,005	(14,234)	(6,310)
Loss on early extinguishment of debt	899	0	300
Increase (decrease) in cash flows from changes in assets and liabilities, net of acquired assets
Accounts receivable	(9,159)	13,920	(13,943)
Inventories	(37,806)	(30,397)	(117)
Accounts payable	4,890	(2,977)	38
Income taxes	(1,675)	(1,644)	(1,867)
Accrued compensation and benefits	11,067	(4,123)	9,957
Other assets	(24,005)	(8,170)	(22,263)
Other liabilities	991	3,488	4,548
Net cash provided by operating activities	111,770	64,531	95,133
Cash flows from investing activities:
Purchases of property, plant and equipment	(14,866)	(13,013)	(20,066)
Payments related to business acquisitions and asset acquisitions, net of cash acquired	0	(3,852)	(367,596)
Proceeds from Sale of Property Held-for-sale	0	3,227	0
Net cash used in investing activities	(14,866)	(13,638)	(387,662)
Cash flows from financing activities:
Payments on term loan	(66,654)	(13,250)	(154,312)
Proceeds from term loan	52,411	0	265,000
Payments on revolving line of credit	(393,753)	(212,000)	(484,000)
Proceeds from revolving line of credit	326,753	199,000	392,000
Proceeds from Convertible Debt	0	0	345,000
Payments on mortgage notes	0	0	(836)
Payments Related to Contingent Consideration	(6,222)	(2,671)	(6,466)
Payments related to debt issuance costs	(2,000)	(3,153)	(16,210)
Dividends paid on common stock	(23,256)	(22,818)	(22,600)
Purchase of Convertible Notes Hedges	0	0	(51,198)
Proceeds from Issuance of Warrants	0	0	30,567
Other, net	11,173	2,833	3,936
Net cash provided by (used in) financing activities	(101,548)	(52,059)	300,881
Effect of exchange rate changes on cash and cash equivalents	(1,865)	2,666	(7)
Net increase (decrease) in cash and cash equivalents	(6,509)	1,500	8,345
Cash and cash equivalents at beginning of year	27,356	25,856	17,511
Cash and cash equivalents at end of year	20,847	27,356	25,856
Non-cash investing and financing activities:
Contractual obligations from asset acquisition	0	0	5,639
Dividends payable	5,874	5,775	5,684
Cash paid during the year for:
Interest Paid, Excluding Capitalized Interest, Operating Activities	21,797	30,448	27,274
Income taxes	$ 8,559	$ 9,120	$ 10,576

Operations and Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Operations and Significant Accounting Policies

Organization and operations

CONMED Corporation (“CONMED”, the “Company”, “we” or “us”) is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology.

Principles of consolidation

The consolidated financial statements include the accounts of CONMED Corporation and its controlled subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Use of estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and judgments which affect the reported amounts of assets, liabilities, related disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. The Company considered COVID-19 related impacts on its estimates, as appropriate, within its consolidated financial statements and there may be changes to those estimates in future periods. The Company believes that the accounting estimates are appropriate after giving consideration to the increased uncertainties surrounding the severity and duration of the COVID-19 pandemic. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ from those estimates.

Cash and cash equivalents

We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.

Inventories

Inventories are valued at the lower of cost and net realizable value determined on the FIFO (first-in, first-out) cost method.

We write-off excess and obsolete inventory resulting from the inability to sell our products at prices in excess of current carrying costs. We make estimates regarding the future recoverability of the costs of our products and record a provision for excess and obsolete inventories based on historical experience and expected future trends.

Property, plant and equipment

Property, plant and equipment are stated at cost and depreciated using the straight-line method over the following estimated useful lives:


			Building and improvements			12 to 40 years
			Leasehold improvements			Shorter of life of asset or life of lease
			Machinery and equipment			2 to 15 years

Leases

The Company leases various manufacturing facilities, office facilities and equipment under operating and finance leases. We determine if an arrangement is a lease at inception. Right-of-use ("ROU") assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Certain of our leases include variable lease payments, mainly when a lease is tied to an index rate. These variable lease payments are recorded as expense in the period incurred and are not material.

The Company has lease agreements with lease and non-lease components, which we account for separately. For certain equipment leases, we apply a portfolio approach to efficiently account for the operating lease ROU assets and lease liabilities. We also elected the short-term lease exemption and do not recognize leases with terms less than one year on the balance sheet. The related short-term lease expense is not material.

Our leases have remaining lease terms of one year to ten years, some of which include options to extend the leases for up to five years, and some of which include options to terminate the leases within one year. We only account for such extensions or early terminations when it is reasonably certain we will exercise such options. Refer to Note 5 for further detail on leases.

The Company places certain of our capital equipment with customers on a loaned basis and at no charge in exchange for commitments to purchase related single-use products over time periods generally ranging from one to three years. Placed equipment is loaned and subject to return if minimum single-use purchases are not met. The Company accounts for these placements as operating leases but applies a practical expedient and does not separate the non-lease and lease components from the combined component. Accordingly, the Company accounts for the combined component as a single performance obligation with revenue recognized upon shipment of the related single use-products. The cost of the equipment is amortized over its estimated useful life which is generally five years.

Goodwill and other intangible assets

We have a history of growth through acquisitions. Assets and liabilities of acquired businesses are recorded at their estimated fair values as of the date of acquisition. Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses. Factors that contribute to the recognition of goodwill include synergies expected to increase net sales and profits; acquisition of a talented workforce; cost savings opportunities; the strategic benefit of expanding our presence in core and adjacent markets; and diversifying our product portfolio. Customer and distributor relationships, trademarks, tradenames, developed technology, patents and other intangible assets primarily represent allocations of purchase price to identifiable intangible assets of acquired businesses. Sales representation, marketing and promotional rights represent intangible assets created under our agreement with Musculoskeletal Transplant Foundation (“MTF”).

Goodwill and intangible assets deemed to have indefinite lives are not amortized, but are subject to at least annual impairment testing. It is our policy to perform our annual impairment testing in the fourth quarter. The identification and measurement of goodwill impairment involves the estimation of the fair value of our business. Estimates of fair value are based on the best information available as of the date of the assessment. We completed our goodwill impairment testing of our single reporting unit during the fourth quarter of 2021. We performed our impairment test utilizing the market capitalization approach to determine whether the fair value of a reporting unit is less than its carrying amount. Based upon our assessment, the fair value of our reporting unit continues to exceed carrying value.

Intangible assets with a finite life are amortized over the estimated useful life of the asset and are evaluated each reporting period to determine whether events and circumstances warrant a revision to the remaining period of amortization. Intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. The carrying amount of an intangible asset subject to amortization is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use of the asset. An impairment loss is recognized by reducing the carrying amount of the intangible asset to its current fair value.

For all other indefinite-lived intangible assets, we perform a qualitative impairment test. Based upon this assessment, we have determined that our indefinite-lived intangible assets are not impaired.

Other long-lived assets

We review other long-lived assets consisting of property, plant and equipment and field inventory for impairment whenever events or circumstances indicate that such carrying amounts may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value to its current fair value.

The Company maintains field inventory consisting of capital equipment for customer demonstration and evaluation purposes. Field inventory is generally not sold to customers but rather continues to be used over its useful life for demonstration, evaluation and loaner purposes. An annual wear and tear provision has been recorded on field inventory. The net book value of such equipment at December 31, 2021 and 2020 is $42.5 million and $43.3 million, respectively.

Translation of foreign currency financial statements

Assets and liabilities of foreign subsidiaries have been translated into United States dollars at the applicable rates of exchange in effect at the end of the period reported. Revenues and expenses have been translated at the applicable weighted average rates of exchange in effect during the period reported. Translation adjustments are reflected in accumulated other comprehensive loss. Transaction gains and losses are included in net income.

Foreign exchange and hedging activity

We manage our foreign currency transaction risks through the use of forward contracts to hedge forecasted cash flows associated with foreign currency transaction exposures. We account for these forward contracts as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in current earnings but are included in accumulated other comprehensive loss. These changes in fair value will be reclassified into earnings as a component of sales or cost of sales when the forecasted transaction occurs.

We also enter into forward contracts to exchange foreign currencies for United States dollars in order to hedge our currency transaction exposures on intercompany receivables denominated in foreign currencies. These forward contracts settle each month at month-end, at which time we enter into new forward contracts. We have not designated these forward contracts as hedges and have not applied hedge accounting to them. We record these forward contracts at fair value with resulting gains and losses included in selling and administrative expense in the consolidated statements of comprehensive income.

Income taxes

Deferred income tax assets and liabilities are based on the difference between the financial statement and tax basis of assets and liabilities and operating loss and tax credit carryforwards as measured by the enacted tax rates that are anticipated to be in effect in the respective jurisdictions when these differences reverse. The deferred income tax provision generally represents the net change in the assets and liabilities for deferred income taxes. A valuation allowance is established when it is necessary to reduce deferred income tax assets to amounts for which realization is likely. In assessing the need for a valuation allowance, we estimate future taxable income, considering the feasibility of ongoing tax planning strategies and the realizability of tax loss carryforwards following tax law ordering rules. Valuation allowances related to deferred tax assets may be impacted by changes to tax laws, changes to statutory tax rates, reversal of temporary differences and ongoing and future taxable income levels.

Deferred income taxes are not provided on the unremitted earnings of certain subsidiaries outside of the United States earned after December 31, 2017 as it is expected that these earnings are permanently reinvested. Such earnings may become taxable upon a repatriation of assets from a subsidiary or the sale or liquidation of a subsidiary. Deferred income taxes are provided when the Company no longer considers subsidiary earnings to be permanently invested, such as in situations where the Company’s subsidiaries plan to make future dividend distributions.

Revenue recognition

The Company recognizes revenue when we have satisfied a performance obligation by transferring a promised good or service (that is an asset) to a customer. An asset is transferred when the customer obtains control of that asset. The following policies apply to our major categories of revenue transactions:

•Revenue is recognized when product is shipped at which point the performance obligation is satisfied and the customer obtains control of the product.

•We place certain of our capital equipment with customers on a loaned basis and at no charge in exchange for commitments to purchase related single-use products over time periods generally ranging from one to three years. In these circumstances, no revenue is recognized upon capital equipment shipment as the equipment is loaned and subject to return if certain minimum single-use purchases are not met. Revenue is recognized upon the sale and shipment of the related single-use products. The cost of the equipment is amortized over its estimated useful life which is generally five years.

•We recognize revenues in accordance with the terms of our agreement with MTF on a net basis as our role is that of an agent earning a commission or fee. MTF is responsible for the sourcing, processing and distribution of allograft tissue for sports medicine procedures while the Company represents, markets and promotes MTF’s sports medicine allograft tissues to customers. The Company is paid a fee by MTF which is calculated as a percentage of the net amounts invoiced by MTF to customers for sports medicine allograft tissues. The Company accounts for the services provided to MTF as a series of distinct performance obligations and each service is recognized over time as MTF simultaneously receives and consumes the benefit.

•Product returns are only accepted at the discretion of the Company and in accordance with our “Returned Goods Policy”. Historically, the level of product returns has not been significant. We accrue for sales returns, rebates and allowances based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.

•Our terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are provided for capital equipment sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.

•Amounts billed to customers related to shipping and handling have been included in net sales. Shipping and handling costs included in selling and administrative expense were $17.0 million, $14.6 million and $15.4 million for 2021, 2020 and 2019, respectively.

•We sell to a diversified base of customers around the world and, therefore, believe there is no material concentration of credit risk.

•We assess the risk of loss on accounts receivable and adjust the allowance for doubtful accounts based on this risk assessment. We do so by applying historical loss rates to our accounts receivable aging schedule to estimate expected credit losses. We further adjusted expected credit losses for specifically identified and forecasted credit losses. Historically, losses on accounts receivable have not been material. Management believes that the allowance for doubtful accounts is adequate to provide for probable losses resulting from accounts receivable.

•We sell extended warranties to customers that are typically for a period of one to three years. The related revenue is recorded as a contract liability and recognized over the life of the contract on a straight-line basis, which is reflective of our obligation to stand ready to provide repair services.

Please refer to Note 10 for further detail on revenue.

Earnings per share

Basic earnings per share (“basic EPS”) is computed by dividing net income by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding resulting from employee stock options, restricted stock units, performance share units and stock appreciation rights during the period. The following table sets forth the computation of basic and diluted earnings per share at December 31, 2021, 2020 and 2019, respectively:


	2021		2020		2019

Net income	$	62,542	$	9,517	$	28,620

Basic-weighted average shares outstanding	29,162		28,581		28,325

Effect of dilutive potential securities	3,054		883		1,170

Diluted-weighted average shares outstanding	32,216		29,464		29,495

Net income (per share)
Basic	$	2.14	$	0.33	$	1.01
Diluted	1.94		0.32		0.97

The shares used in the calculation of diluted EPS exclude options and stock appreciation rights ("SARs") to purchase shares where the exercise price was greater than the average market price of common shares for the year and the effect of the inclusion would be anti-dilutive. Such shares aggregated approximately 0.6 million, 1.4 million and 0.7 million at December 31, 2021, 2020 and 2019, respectively. As more fully described in Note 7, our 2.625% convertible notes due in 2024 (the “Notes”) are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock.

The following is intended to describe the impact of the Notes and related hedge transactions on the calculation of diluted EPS. Additional shares to be issued pursuant to the terms of the Notes and related hedge transactions, if any, would occur at maturity.

The calculation of diluted EPS would include potential diluted shares upon conversion of the Notes when the average market price per share of our common stock for the period, is greater than the conversion price of the Notes of $88.80. We intend to settle in cash the principal outstanding and use the treasury stock method when calculating their potential dilutive effect, if any.

During the year ended December 31, 2021, our average share price exceeded the conversion price of the Notes and we included in our diluted share count 1.3 million shares assumed to be issued if the Notes were converted. During the years ended December 31, 2020 and 2019, our average share price had not exceeded the conversion price of the Notes; therefore, under the net share settlement method, there were no potential shares issuable under the Notes to be used in the calculation of diluted EPS.

We previously entered into convertible note hedge transactions to increase the effective conversion price of the Notes to $114.92. However, our convertible notes hedges are not included when calculating potential dilutive shares since their effect is always anti-dilutive.

Concurrently with entering into the hedge transactions, we also previously entered into warrant transactions under which we agreed to sell shares of our common stock at $114.92.

The calculation of diluted EPS also includes potential diluted shares to be issued under the warrants when the average market price per share of our common stock for the period is greater than $114.92. During the year ended December 31, 2021, our average share price exceeded $114.92 and we therefore included in our diluted share count an additional 0.5 million shares assumed to be issued under the warrants. During the years ended December 31, 2020 and 2019, our average share price had not exceeded $114.92; therefore, there were no potential shares issuable under the warrants to be used in the calculation of diluted EPS.

Stock-based compensation

All share-based payments to employees, including grants of employee stock options, restricted stock units, performance share units and stock appreciation rights are recognized in the financial statements at their fair values. Compensation expense is generally recognized using a straight-line method over the vesting period. Compensation expense for performance share units is recognized using the graded vesting method.

We issue shares under our stock based compensation plans out of treasury stock whereby treasury stock is reduced by the weighted average cost of such treasury stock. To the extent there is a difference between the cost of the treasury stock and the exercise price of shares issued under stock based compensation plans, we record gains to paid in capital; losses are recorded to paid in capital to the extent any gain was previously recorded, otherwise the loss is recorded to retained earnings.

Accumulated other comprehensive loss

Accumulated other comprehensive loss consists of the following:


	Cash Flow Hedging Gain (Loss)		Pension Liability		Foreign Currency Translation Adjustments		Accumulated Other Comprehensive Loss

Balance, December 31, 2018	$	4,085	$	(31,718)	$	(28,104)	$	(55,737)

Other comprehensive income (loss) before reclassifications, net of tax	2,936		(2,158)		25		803
Amounts reclassified from accumulated other comprehensive income before tax(a)	(8,607)		2,881		—		(5,726)
Income tax	2,079		(696)		—		1,383

Net current-period other comprehensive income (loss)	(3,592)		27		25		(3,540)

Balance, December 31, 2019	$	493	$	(31,691)	$	(28,079)	$	(59,277)

Other comprehensive income (loss) before reclassifications, net of tax	(5,393)		(7,068)		6,963		(5,498)
Amounts reclassified from accumulated other comprehensive income (loss) before tax(a)	(1,378)		2,821		—		1,443
Income tax	333		(682)		—		(349)

Net current-period other comprehensive income (loss)	(6,438)		(4,929)		6,963		(4,404)

Balance, December 31, 2020	$	(5,945)	$	(36,620)	$	(21,116)	$	(63,681)

Other comprehensive income (loss) before reclassifications, net of tax	6,560		4,426		(7,072)		3,914
Amounts reclassified from accumulated other comprehensive income (loss) before tax(a)	4,010		3,327		—		7,337
Income tax	(969)		(804)		—		(1,773)

Net current-period other comprehensive income (loss)	9,601		6,949		(7,072)		9,478

Balance, December 31, 2021	$	3,656	$	(29,671)	$	(28,188)	$	(54,203)

(a) The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 16 and Note 12, respectively, for further details.

Business Acqusition

12 Months Ended

Dec. 31, 2021

Business Combinations [Abstract]

Business Acquisition

Business Acquisitions

On February 11, 2019 we acquired Buffalo Filter, LLC and all of the issued and outstanding common stock of Palmerton Holdings, Inc. from Filtration Group FGC LLC (the "Buffalo Filter Acquisition") for approximately $365 million in cash. Buffalo Filter develops, manufactures and markets smoke evacuation technologies that are complementary to our general surgery offering. The business combination was funded through a combination of cash on hand and long-term borrowings as further described in Note 7.

The unaudited pro forma information for the year ended December 31, 2019, assuming the Buffalo Filter Acquisition occurred as of January 1, 2018 is presented below. This information has been prepared for comparative purposes only and does not purport to be indicative of the results of operations which actually would have resulted had the Buffalo Filter acquisition occurred on the dates indicated, or which may result in the future.


	2019
Net sales	$	960,115
Net income	44,361

These pro forma results include certain adjustments, primarily due to increases in amortization expense due to fair value adjustments of intangible assets, increases in interest expense due to additional borrowings incurred to finance the acquisition, and acquisition related costs including transaction costs such as legal, accounting, valuation and other professional services as well as integration costs such as severance and retention.

Net sales associated with Buffalo Filter of $49.6 million have been recorded in the consolidated statement of comprehensive income for the year ended December 31, 2019. It is impracticable to determine the earnings recorded in the consolidated statement of comprehensive income for the year ended December 31, 2019 as these amounts are not separately measured.

Inventories

12 Months Ended

Dec. 31, 2021

Inventory Disclosure [Abstract]

Inventories

Inventories consist of the following at December 31:


	2021		2020
Raw materials	$	83,386	$	71,807
Work in process	17,449		15,864
Finished goods	130,809		107,197
	$	231,644	$	194,868

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant and equipment consist of the following at December 31:


	2021		2020
Land	$	4,027	$	4,027
Building and improvements	95,518		93,886
Machinery and equipment	256,478		243,810
Construction in progress	16,601		15,680
	372,624		357,403
Less: Accumulated depreciation	(263,761)		(245,996)
	$	108,863	$	111,407

Internal-use software, included in gross machinery and equipment at December 31, 2021 and 2020 was $49.1 million and $50.3 million, respectively, with related accumulated depreciation of $45.3 million and $42.9 million, respectively. Internal use software depreciation expense was $3.3 million, $4.7 million and $4.8 million for the years ended December 31, 2021, 2020 and 2019, respectively. Also, during 2020, we sold a vacant facility for $3.2 million.

Leases

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Leases

Lease costs for the year ended December 31, consist of the following:


	2021		2020		2019
Operating lease cost:
Straight-line lease cost	$	7,720	$	7,255	$	7,780
Right-of-use asset impairment cost	—		—		312
Total operating lease cost	7,720		7,255		8,092
Finance lease cost:
Depreciation	389		355		238
Interest on lease liabilities	30		33		27
Total finance lease cost	419		388		265
Total lease cost	$	8,139	$	7,643	$	8,357

Supplemental balance sheet information related to leases as of December 31, is as follows:


	2021			2020
Operating leases
Other assets	$	19,425		$	21,659

Other current liabilities	$	7,162		$	7,469
Other long-term liabilities	12,726			14,756
Total operating lease liabilities	$	19,888		$	22,225

Finance leases
Property, plant and equipment, gross	$	1,984		$	1,762
Accumulated depreciation	(1,145)			(825)
Property, plant and equipment, net	$	839		$	937

Current portion of long-term debt	$	324		$	197
Long-term debt	240			390
Total finance lease liabilities	$	564		$	587


Weighted average remaining lease term (in years)
Operating leases	3.90 years			3.76 years
Finance leases	3.05 years			3.22 years

Weighted average discount rate
Operating leases	5.02		%	5.00		%
Finance leases	4.47		%	4.93		%

Supplemental cash flow information related to leases for the year ended December 31, was as follows:


	2021		2020		2019

Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	7,791	$	7,535	$	8,459
Financing cash flows from finance leases	287		373		380

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	4,704		4,242		12,800
Finance leases	305		76		563

Maturities of lease liabilities as of December 31, 2021 are as follows:


	Finance Lease		Operating Lease

2022	$	324	$	7,162
2023	188		5,830
2024	62		4,555
2025	8		1,637
2026	5		795
Thereafter	1		2,174
Total lease payments	588		22,153

Less imputed interest	(24)		(2,265)

Total lease liabilities	$	564	$	19,888

As of December 31, 2021, we have entered into approximately $0.1 million of operating leases that have not yet commenced. As of December 31, 2021 we have not entered into any finance leases that have not yet commenced.

Leases

Lease costs for the year ended December 31, consist of the following:


	2021		2020		2019
Operating lease cost:
Straight-line lease cost	$	7,720	$	7,255	$	7,780
Right-of-use asset impairment cost	—		—		312
Total operating lease cost	7,720		7,255		8,092
Finance lease cost:
Depreciation	389		355		238
Interest on lease liabilities	30		33		27
Total finance lease cost	419		388		265
Total lease cost	$	8,139	$	7,643	$	8,357

Supplemental balance sheet information related to leases as of December 31, is as follows:


	2021			2020
Operating leases
Other assets	$	19,425		$	21,659

Other current liabilities	$	7,162		$	7,469
Other long-term liabilities	12,726			14,756
Total operating lease liabilities	$	19,888		$	22,225

Finance leases
Property, plant and equipment, gross	$	1,984		$	1,762
Accumulated depreciation	(1,145)			(825)
Property, plant and equipment, net	$	839		$	937

Current portion of long-term debt	$	324		$	197
Long-term debt	240			390
Total finance lease liabilities	$	564		$	587


Weighted average remaining lease term (in years)
Operating leases	3.90 years			3.76 years
Finance leases	3.05 years			3.22 years

Weighted average discount rate
Operating leases	5.02		%	5.00		%
Finance leases	4.47		%	4.93		%

Supplemental cash flow information related to leases for the year ended December 31, was as follows:


	2021		2020		2019

Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	7,791	$	7,535	$	8,459
Financing cash flows from finance leases	287		373		380

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	4,704		4,242		12,800
Finance leases	305		76		563

Maturities of lease liabilities as of December 31, 2021 are as follows:


	Finance Lease		Operating Lease

2022	$	324	$	7,162
2023	188		5,830
2024	62		4,555
2025	8		1,637
2026	5		795
Thereafter	1		2,174
Total lease payments	588		22,153

Less imputed interest	(24)		(2,265)

Total lease liabilities	$	564	$	19,888

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

The changes in the net carrying amount of goodwill for the years ended December 31, are as follows:


	2021		2020
Balance as of January 1,	$	618,440	$	618,042



Goodwill adjustment resulting from business combinations	—		(1,009)

Foreign currency translation	(912)		1,407

Balance as of December 31,	$	617,528	$	618,440

Total accumulated goodwill impairment losses aggregated $107.0 million at December 31, 2021 and 2020, respectively. During 2019, the Company acquired a distributor and in 2020 recorded a measurement period adjustment related to the acquired distributor.

Other intangible assets consist of the following:


	December 31, 2021					December 31, 2020
	Weighted Average Amortization Period (Years)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Intangible assets with definite lives:	22

Customer and distributor relationships	24	$	342,452	$	(152,934)	$	342,639	$	(134,555)

Sales representation, marketing and promotional rights	25	149,376		(60,000)		149,376		(54,000)

Patents and other intangible assets	16	76,392		(50,890)		73,516		(48,882)

Developed technology	16	106,604		(26,495)		106,604		(19,705)

Intangible assets with indefinite lives:

Trademarks and tradenames		86,544		—		86,544		—

		$	761,368	$	(290,319)	$	758,679	$	(257,142)

Amortization expense related to intangible assets which are subject to amortization totaled $33.3 million, $34.2 million and $32.3 million for the years ending December 31, 2021, 2020 and 2019, respectively, and is included as a reduction of revenue (for amortization related to our sales representation, marketing and promotional rights) and in selling and administrative expense (for all other intangible assets) in the consolidated statements of comprehensive income.

The estimated amortization expense related to intangible assets at December 31, 2021 and for each of the five succeeding years is as follows:


	Amortization included in expense		Amortization recorded as a reduction of revenue		Total
2022	$	26,397	$	6,000	$	32,397
2023	25,665		6,000		31,665
2024	24,947		6,000		30,947
2025	25,140		6,000		31,140
2026	24,651		6,000		30,651

Long Term Debt

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

Long Term Debt

Long-term debt consists of the following at December 31:


	2021		2020
Revolving line of credit	$	140,000	$	207,000
Term loan, net of deferred debt issuance costs of $1,373 and $1,668 in 2021 and 2020, respectively	226,196		240,145
2.625% convertible notes, net of deferred debt issuance costs of $3,700 and $5,475 in 2021 and 2020, respectively, and unamortized discount of $23,404 and $33,620 in 2021 and 2020, respectively	317,896		305,904
Financing leases	564		587
Total debt	684,656		753,636
Less: Current portion	12,249		18,415
Total long-term debt	$	672,407	$	735,221

On July 16, 2021, we entered into a seventh amended and restated senior credit agreement consisting of: (a) a $233.5 million term loan facility and (b) a $585.0 million revolving credit facility. The revolving credit facility will terminate and the loans outstanding under the term loan facility will expire on July 16, 2026. The term loan is payable in quarterly installments increasing over the term of the facility. Proceeds from the term loan facility and borrowings under the revolving credit facility were used to repay the then existing senior credit agreement. Interest rates are at LIBOR (subject to 0.125% floor) plus an interest rate margin of 1.50% (1.625% at December 31, 2021). For borrowings where we elect to use the alternate base rate, the initial base rate is the greatest of (i) the Prime Rate, (ii) the Federal Funds Rate plus 0.50% or (iii) the one-month Adjusted LIBOR plus 1.00%, plus, in each case, an interest rate margin.

There were $227.6 million in borrowings outstanding on the term loan facility as of December 31, 2021. There were $140.0 million in borrowings outstanding under the revolving credit facility as of December 31, 2021. Our available borrowings on the revolving credit facility at December 31, 2021 were $442.5 million with approximately $2.5 million of the facility set aside for outstanding letters of credit. The carrying amounts of the term loan and revolving credit facility approximate fair value.

The seventh amended and restated senior credit agreement is collateralized by substantially all of our personal property and assets. The seventh amended and restated senior credit agreement contains covenants and restrictions which, among other things, require the maintenance of certain financial ratios and restrict dividend payments and the incurrence of certain indebtedness and other activities, including acquisitions and dispositions. We were in full compliance with these covenants and restrictions as of December 31, 2021. We are also required, under certain circumstances, to make mandatory prepayments from net cash proceeds from any issuance of equity and asset sales.

On January 29, 2019, we issued $345.0 million in 2.625% convertible notes due in 2024 (the "Notes"). Interest is payable semi-annually in arrears on February 1 and August 1 of each year, commencing August 1, 2019. The Notes will mature on February 1, 2024, unless earlier repurchased or converted. The Notes represent subordinated unsecured obligations and are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock. The Notes may be converted at an initial conversion rate of 11.2608 shares of our common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $88.80 per share of common stock). Holders of the Notes may convert the Notes at their option at any time on or after November 1, 2023 through the second scheduled trading day preceding the maturity date. Holders of the Notes will also have the right to convert the Notes prior to November 1, 2023, but only upon the occurrence of specified events. The conversion rate is subject to anti-dilution adjustments if certain events occur. A portion of the net proceeds from the offering of the Notes were used as part of the financing for the Buffalo Filter acquisition and $21.0 million were used to pay the cost of certain convertible notes hedge transactions as further described below.

Our effective borrowing rate for nonconvertible debt at the time of issuance of the Notes was estimated to be 6.14%, which resulted in $51.6 million of the $345.0 million aggregate principal amount of Notes issued, or $39.1 million after taxes, being attributable to equity. For the years ended December 31, 2021, 2020 and 2019, we have recorded interest expense related to the amortization of debt discount on the Notes of $10.2 million, $9.7 million and $8.3 million respectively, at the effective interest rate of 6.14%. The debt discount on the Notes is being amortized through February 2024. For the years ended December 31, 2021, 2020 and 2019, we have recorded interest expense on the Notes of $9.1 million, $9.1 million and $8.4 million, respectively, at the contractual coupon rate of 2.625%.

The estimated fair value of the Notes was approximately $576.0 million as of December 31, 2021 based on a market approach which represents a Level 2 valuation in the fair value hierarchy. The estimated fair value was determined based on the estimated or actual bids and offers of the Notes in an over-the-counter market transaction on the last business day of the period.

In connection with the offering of the Notes, we entered into convertible note hedge transactions with a number of financial institutions (each, an “option counterparty”). The convertible note hedge transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the Notes, the number of shares of our common stock underlying the Notes. Concurrently with entering into the convertible note hedge transactions, we also entered into separate warrant transactions with each option counterparty whereby we sold to such option counterparty warrants to purchase, subject to customary anti-dilution adjustments, the same number of shares of our common stock.

The convertible note hedge transactions are expected generally to reduce the potential dilution upon conversion of the Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, in the event that the market price per share of our common stock, as measured under the terms of the convertible note hedge transactions, is greater than the strike price of the convertible note hedge transactions, which initially corresponds to the conversion price of the Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the Notes. If, however, the market price per share of our common stock, as measured under the terms of the warrant transactions, exceeds the strike price ($114.92) of the warrants, there would nevertheless be dilution to the extent that such market price exceeds the strike price of the warrants, unless we elect to settle the warrants in cash.

See additional discussion regarding a new accounting standard and related impact on our Notes in Note 17.

The scheduled maturities of long-term debt outstanding at December 31, 2021 are as follows:


2022	$	11,925
2023	14,906
2024	365,869
2025	23,850
2026	296,019

The above amounts exclude debt discount,deferred debt issuance costs and financing leases.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

The provision (benefit) for income taxes for the years ended December 31, 2021, 2020 and 2019 consists of the following:


	2021		2020		2019
Current tax expense (benefit):
Federal	$	(97)	$	(729)	$	96
State	609		86		444
Foreign	7,046		6,963		8,375
	7,558		6,320		8,915
Deferred income tax expense (benefit):
Federal	3,466		(12,253)		(3,970)
State	1,449		(1,173)		(938)
Foreign	(1,910)		(808)		(1,402)
	3,005		(14,234)		(6,310)

Provision (benefit) for income taxes	$	10,563	$	(7,914)	$	2,605

A reconciliation between income taxes computed at the statutory federal rate and the provision (benefit) for income taxes for the years ended December 31, 2021, 2020 and 2019 follows:


	2021		2020		2019
Tax provision at statutory rate based on income before income taxes	21.0	%	21.0	%	21.0	%

Stock-based compensation	(9.4)		(267.7)		(15.4)

Federal research credit	(2.3)		(124.2)		(4.0)

Valuation allowance	(2.2)		49.7		1.9

US tax on worldwide earnings at different rates	(0.4)		(123.7)		7.9

Settlement of taxing authority examinations	—		(122.9)		(7.7)

Tax treaty protocols	—		—		(2.9)

Non deductible/non-taxable items	0.8		28.6		2.8

Foreign income taxes	3.1		79.9		4.5

State income taxes, net of federal tax benefit	3.7		(24.5)		0.3







Other, net	0.1		(10.1)		(0.1)

	14.4	%	(493.9)	%	8.3	%

The Company has elected to account for Global Intangible Low Tax Income ("GILTI") using the period cost method. The net impact of GILTI including the allowable GILTI deduction is presented in the rate reconciliation as a component of “US tax on worldwide earnings at different rates” and is offset in part by the Foreign Derived Intangible Income deduction (“FDII”).

The tax effects of the significant temporary differences which comprise the deferred income tax assets and liabilities at December 31, 2021 and 2020 are as follows:


	2021		2020
Assets:
Inventory	$	4,694	$	4,649
Net operating losses	18,383		22,197
Capitalized research and development	4,173		5,187
Deferred compensation	2,563		2,240
Accounts receivable	3,147		2,784
Compensation and benefits	6,583		7,540
Accrued pension	3,930		5,348
Research and development credit	15,542		13,540

Convertible notes hedge	4,869		6,999
Lease liabilities	3,573		4,452
Other	5,741		6,793
Less: valuation allowances	(786)		(2,721)
	72,412		79,008

Liabilities:
Goodwill and intangible assets	106,065		104,119
Depreciation	2,546		2,512
State taxes	11,833		9,614
Unremitted foreign earnings	2,449		2,423
Convertible notes debt discount	4,915		7,060
Lease right-of-use assets	3,484		4,313

	131,292		130,041

Net liability	$	(58,880)	$	(51,033)

Income before income taxes consists of the following U.S. and foreign income:


	2021		2020		2019
U.S. income	$	45,260	$	(16,026)	$	5,332
Foreign income	27,845		17,629		25,893
Total income	$	73,105	$	1,603	$	31,225

As of December 31, 2021, the amount of federal net operating loss carryforward was $15.7 million and begins to expire in 2027. As of December 31, 2021, the amount of federal research credit carryforward available was $15.5 million. These credits begin to expire in 2027.

We have accrued tax liabilities related to the amount of unremitted earnings at December 31, 2017 and certain subsequent unremitted earnings as these are not considered permanently reinvested. Deferred taxes have not been accrued on unremitted earnings subsequent to December 31, 2017 that are considered permanently reinvested. The amount of such untaxed foreign earnings for the periods occurring after December 2017 totaled $20.3 million. If we were to repatriate these funds, we would be required to accrue and pay taxes on such amounts. The Company has estimated foreign withholding taxes of $0.9 million would be due if these earnings were repatriated.

The Company is subject to taxation in the United States and various states and foreign jurisdictions. Taxing authority examinations can involve complex issues and may require an extended period of time to resolve. Our federal income tax returns have been examined by the Internal Revenue Service (“IRS”) for calendar years ending through 2019.

We recognize tax liabilities in accordance with the provisions for accounting for uncertainty in income taxes. Such guidance prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

The following table summarizes the activity related to our unrecognized tax benefits for the years ending December 31,:


	2021		2020		2019
Balance as of January 1,	$	200	$	2,170	$	3,073



Increases for positions taken in current periods	—		—		1,650

Decreases in unrecorded tax positions related to settlement with the taxing authorities	—		(1,970)		(2,404)

Decreases in unrecorded tax positions related to lapse of statute of limitations	—		—		(149)

Balance as of December 31,	$	200	$	200	$	2,170

If the total unrecognized tax benefits of $0.2 million at December 31, 2021 were recognized, it would reduce our annual effective tax rate. The amount of interest accrued in 2019, 2020 and 2021 related to these unrecognized tax benefits was not material and is included in the provision (benefit) for income taxes in the consolidated statements of comprehensive income.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Shareholders' Equity

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Shareholders' Equity

Shareholders’ Equity

On February 29, 2012, the Board of Directors adopted a cash dividend policy and declared an initial quarterly dividend of $0.15 per share. On October 28, 2013, the Board of Directors increased the quarterly dividend to $0.20 per share. The total dividend per share was $0.80 for each of 2021, 2020 and 2019. The fourth quarter dividend for 2021 was paid on January 5, 2022 to shareholders of record as of December 15, 2021. The total dividend payable was $5.9 million and $5.8 million at December 31, 2021 and 2020, respectively, and is included in other current liabilities in the consolidated balance sheet.

Our shareholders have authorized 500,000 shares of preferred stock, par value $.01 per share, which may be issued in one or more series by the Board of Directors without further action by the shareholders. As of December 31, 2021 and 2020, no preferred stock had been issued.

Our Board of Directors has authorized a $200.0 million share repurchase program. Through December 31, 2021, we have repurchased a total of 6.1 million shares of common stock aggregating $162.6 million under this authorization and have $37.4 million remaining available for share repurchases. The repurchase program calls for shares to be purchased in the open market or in private transactions from time to time. We may suspend or discontinue the share repurchase program at any time. During 2021, 2020, and 2019 we did not repurchase any shares.

We have reserved 6.7 million shares of common stock for issuance to employees and directors under two shareholder approved share-based compensation plans (the "Plans") of which approximately 3.4 million shares remain available for grant at December 31, 2021. The exercise price on all outstanding stock options and stock appreciation rights (“SARs”) is equal to the quoted fair market value of the stock at the date of grant. Restricted stock units (“RSUs”) and performance stock units (“PSUs”) are valued at the market value of the underlying stock on the date of grant. Stock options, SARs, RSUs and PSUs are generally non-transferable other than on death and generally become exercisable over a 4 to 5 year period from date of grant. Stock options and SARs expire 10 years from date of grant. SARs are only settled in shares of the Company’s stock. The issuance of shares pursuant to the exercise of stock options and SARs and vesting of RSUs and PSUs are from the Company’s treasury stock.

Total pre-tax stock-based compensation expense recognized in the consolidated statements of comprehensive income was $16.3 million, $13.1 million and $11.8 million for the years ended December 31, 2021, 2020 and 2019, respectively. These amounts are included in selling and administrative expense. Tax related benefits of $3.9 million, $3.2 million and $2.8 million were also recognized for the years ended December 31, 2021, 2020 and 2019, respectively. Cash received from the exercise of stock options was $19.6 million, $13.7 million and $7.7 million for the years ended December 31, 2021, 2020 and 2019, respectively, and is reflected in cash flows from financing activities in the consolidated statements of cash flows.

The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options and SARs at the date of grant. Use of a valuation model requires management to make certain assumptions with respect to select model inputs. Expected volatilities are based upon historical volatility of the Company’s stock over a period equal to the expected life of each stock option and SAR grant. The risk free interest rate is based on the stock option and SAR grant date for a traded U.S. Treasury bond with a maturity date closest to the expected life. The expected annual dividend yield is based on the Company's anticipated cash dividend payouts. The expected life represents the period of time that the stock options and SARs are expected to be outstanding based on a study of historical data of option holder exercise and termination behavior. Forfeitures are recognized as incurred.

The following table illustrates the assumptions used in estimating fair value in the years ended December 31, 2021, 2020 and 2019:


	2021			2020			2019
Grant date fair value of stock options and SARs	$	42.47		$	22.62		$	20.59
Expected stock price volatility	39.27		%	26.89		%	26.59		%
Risk-free interest rate	0.81		%	0.89		%	2.58		%
Expected annual dividend yield	0.64		%	0.82		%	1.08		%
Expected life of options & SARs (years)	5.5			5.5			5.6

The following table illustrates the stock option and SAR activity for the year ended December 31, 2021:


	Number of Shares (in 000’s)	Weighted- Average Exercise Price
Outstanding at December 31, 2020	3,336	$	66.76

Granted	701	$	123.21
Forfeited	(177)	$	82.35
Exercised	(596)	$	51.59

Outstanding at December 31, 2021	3,264	$	80.79
Exercisable at December 31, 2021	1,284	$	59.40
Stock options & SARs expected to vest	1,980	$	94.67

The weighted average remaining contractual term for SARs and stock options outstanding and exercisable at December 31, 2021 was 7.0 years and 5.5 years, respectively. The aggregate intrinsic value of SARs and stock options outstanding and exercisable at December 31, 2021 was $199.0 million and $105.8 million, respectively. The aggregate intrinsic value of stock options and SARs exercised during the years ended December 31, 2021, 2020 and 2019 was $49.2 million, $26.6 million and $17.0 million, respectively.

The following table illustrates the RSU activity for the year ended December 31, 2021:


	Number of Shares (in 000’s)	Weighted- Average Grant-Date Fair Value
Outstanding at December 31, 2020	61	$	77.03

Granted	21	$	129.94
Vested	(30)	$	73.11
Forfeited	(1)	$	55.96

Outstanding at December 31, 2021	51	$	101.55

The weighted average fair value of RSU awards granted in the years ended December 31, 2021, 2020 and 2019 was $129.94, $85.45 and $78.64, respectively.

The total fair value of RSUs and PSUs vested was $2.2 million, $6.2 million and $2.8 million for the years ended December 31, 2021, 2020 and 2019, respectively.

As of December 31, 2021, there was $45.4 million of total unrecognized compensation cost related to nonvested stock options, SARs and RSUs granted under the Plans which is expected to be recognized over a weighted average period of 3.5 years.

We offer to our employees a shareholder-approved Employee Stock Purchase Plan (the “Employee Plan”), under which we reserved 1.0 million shares of common stock for issuance to our employees. The Employee Plan provides employees with the opportunity to invest from 1% to 10% of their annual salary to purchase shares of CONMED common stock at a purchase price equal to 95% of the fair market value of the common stock on the exercise date. During 2021, we issued approximately 13,024 shares of common stock under the Employee Plan. No stock-based compensation expense has been recognized in the accompanying consolidated financial statements as a result of common stock issuances under the Employee Plan.

Revenues

12 Months Ended

Dec. 31, 2021

Revenues [Abstract]

Revenues

The following tables present revenue disaggregated by product line and timing of revenue recognition for the years ended December 31, 2021, 2020 and 2019:


	2021
	Orthopedic Surgery		General Surgery		Total
Timing of Revenue Recognition
Goods transferred at a point in time	$	398,963	$	567,244	$	966,207
Services transferred over time	39,461		4,967		44,428
Total sales from contracts with customers	$	438,424	$	572,211	$	1,010,635


	2020
	Orthopedic Surgery		General Surgery		Total
Timing of Revenue Recognition
Goods transferred at a point in time	$	340,318	$	484,147	$	824,465
Services transferred over time	34,387		3,607		37,994
Total sales from contracts with customers	$	374,705	$	487,754	$	862,459


	2019
	Orthopedic Surgery		General Surgery		Total
Timing of Revenue Recognition
Goods transferred at a point in time	$	426,893	$	489,313	$	916,206
Services transferred over time	36,429		2,462		38,891
Total sales from contracts with customers	$	463,322	$	491,775	$	955,097

Revenue disaggregated by primary geographic market where the products are sold is included in Note 11.

Contract liability balances related to the sale of extended warranties to customers are as follows:


	December 31, 2021		December 31, 2020

Contract Liability	$	16,760	$	13,666

Revenue recognized during years ended December 31, 2021, 2020 and 2019 from amounts included in contract liabilities at the beginning of the period were $10.3 million, $9.3 million and $6.8 million, respectively. There were no material contract assets as of December 31, 2021 and December 31, 2020.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

+ Details

Business Segments and Geographic Areas

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Business Segments and Geographic Areas

We are accounting and reporting for our business as a single operating segment entity engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. Our chief operating decision maker (the CEO) evaluates the various global product portfolios on a net sales basis and evaluates profitability, investment, cash flow metrics and allocates resources on a consolidated worldwide basis due to shared infrastructure and resources. Our product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and small bone, large bone and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and fees related to sales representation, promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. These product lines' net sales and primary geographic market where the products are sold, are as follows for the years ended December 31, 2021, 2020 and 2019:


	2021
	Orthopedic Surgery		General Surgery		Total
Primary Geographic Markets
United States	$	158,553	$	393,980	$	552,533
Europe, Middle East & Africa	108,457		81,238		189,695
Asia Pacific	107,590		63,628		171,218
Americas (excluding the United States)	63,824		33,365		97,189
Total sales from contracts with customers	$	438,424	$	572,211	$	1,010,635


	2020
	Orthopedic Surgery		General Surgery		Total
Primary Geographic Markets
United States	$	139,715	$	342,349	$	482,064
Europe, Middle East & Africa	90,998		70,086		161,084
Asia Pacific	93,636		46,961		140,597
Americas (excluding the United States)	50,356		28,358		78,714
Total sales from contracts with customers	$	374,705	$	487,754	$	862,459


	2019
	Orthopedic Surgery		General Surgery		Total
Primary Geographic Markets
United States	$	179,419	$	337,246	$	516,665
Europe, Middle East & Africa	118,301		64,248		182,549
Asia Pacific	101,333		59,277		160,610
Americas (excluding the United States)	64,269		31,004		95,273
Total sales from contracts with customers	$	463,322	$	491,775	$	955,097

Sales are attributed to countries based on the location of the customer. There were no significant investments in long-lived assets located outside the United States at December 31, 2021 and 2020. No single customer represented over 10% of our consolidated net sales for the years ended December 31, 2021, 2020 and 2019.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Employee Benefit Plans

12 Months Ended

Dec. 31, 2021

Retirement Benefits [Abstract]

Employee Benefit Plans

We sponsor an employee savings plan (“401(k) plan”) covering substantially all of our United States based employees. We also sponsor a defined benefit pension plan (the “pension plan”) that was frozen in 2009. It covered substantially all our United States based employees at the time it was frozen.

Total employer contributions to the 401(k) plan were $9.2 million, $8.9 million and $9.1 million during the years ended December 31, 2021, 2020 and 2019, respectively.

We use a December 31, measurement date for our pension plan. Cumulative gains and losses in excess of 10% of the greater of the benefit obligation or the market-related value of assets are amortized on a straight-line basis over the lesser of the expected average remaining life expectancy of the plan's participants or 12 years. The limit of 12 years is adjusted to reflect the percentage change in the average remaining service period for the plan's active membership.

The following table provides a reconciliation of the projected benefit obligation, plan assets and funded status of the pension plan at December 31:


	2021		2020
Accumulated benefit obligation	$	95,508	$	101,242

Change in benefit obligation
Projected benefit obligation at beginning of year	$	101,242	$	92,052
Service cost	991		717
Interest cost	1,803		2,555
Actuarial loss (gain)	(3,427)		10,963
Benefits paid	(2,703)		(1,933)
Settlements	(2,398)		(3,112)
Projected benefit obligation at end of year	$	95,508	$	101,242

Change in plan assets
Fair value of plan assets at beginning of year	$	76,940	$	75,321
Actual gain on plan assets	7,565		6,664
Benefits paid	(2,703)		(1,933)
Settlements	(2,398)		(3,112)
Fair value of plan assets at end of year	$	79,404	$	76,940

Funded status	$	(16,104)	$	(24,302)

The projected benefit obligation decreased $5.7 million as of December 31, 2021 mainly due to the increase in the discount rate from 2.44% at December 31, 2020 to 2.81% at December 31, 2021.

Amounts recognized in the consolidated balance sheets consist of the following at December 31,:


	2021		2020
Other long-term liabilities	$	(16,104)	$	(24,302)
Accumulated other comprehensive loss	(39,122)		(48,285)

Accumulated other comprehensive loss for the years ended December 31, 2021 and 2020 consists of net actuarial losses not yet recognized in net periodic pension cost (before income taxes).

The following actuarial assumptions were used to determine our accumulated and projected benefit obligations as of December 31,:


	2021		2020
Discount rate	2.81	%	2.44	%

Other changes in plan assets and benefit obligations recognized in other comprehensive income in 2021 and 2020 are as follows:


	2021		2020
Current year actuarial loss (gain)	$	5,836	$	(9,320)
Amortization of actuarial loss	3,327		2,821
Total recognized in other comprehensive income (loss)	$	9,163	$	(6,499)

Net periodic pension cost for the years ended December 31, consists of the following:


	2021		2020		2019
Service cost	$	991	$	717	$	1,010
Interest cost on projected benefit obligation	1,803		2,555		3,130
Expected return on plan assets	(5,155)		(5,021)		(4,725)
Amortization of loss	3,327		2,821		2,881

Net periodic pension cost	$	966	$	1,072	$	2,296

Non-service cost of $0.4 million and $1.3 million is included in other expense in the consolidated statements of comprehensive income for the years ended 2020 and 2019, respectively. Non-service pension cost was immaterial for the year ended 2021.

The following actuarial assumptions were used to determine our net periodic pension benefit cost for the years ended December 31,:


	2021		2020		2019
Discount rate on benefit obligation	2.44	%	3.33	%	4.37	%
Effective rate for interest on benefit obligation	1.83	%	2.88	%	4.01	%
Expected return on plan assets	7.00	%	7.00	%	7.50	%

The Company’s discount rate and mortality assumptions are the significant assumptions in determining the projected benefit obligation of the Company’s pension plan.

The discount rate represents the interest rate used in estimating the present value of projected cash flows to settle the Company’s pension obligations. The discount rate assumption is determined by management using a full yield curve approach, which involves applying the specific spot rates along the yield curve used in the determination of the benefit obligation that correlates to the relevant projected cash flows.

Mortality assumptions are based on published mortality studies developed primarily based on past experience of the broad population and modified for projected longevity trends. The mortality assumptions used for 2021 and 2020 are based on the Pri-2012 Mortality Tables using the MP-2021 and MP-2020, respectively, mortality improvement scales.

In determining the expected return on pension plan assets, we consider the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, we consult with financial and investment management professionals in developing appropriate targeted rates of return.

Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements.

The allocation of plan assets by category is as follows at December 31,:


	Percentage of Pension Plan Assets				Target Allocation
	2021		2020		2022
Equity securities	73	%	76	%	75	%
Debt securities	27	%	24	%	25	%
Total	100	%	100	%	100	%

As of December 31, 2021, the pension plan held 27,562 shares of our common stock, which had a fair value of $3.9 million. We believe that our long-term asset allocation on average will approximate the targeted allocation. We regularly review our actual asset allocation and periodically rebalance the pension plan’s investments to our targeted allocation when deemed appropriate.

FASB guidance defines fair value and establishes a framework for measuring fair value and related disclosure requirements as described in Note 16. Following is a description of the valuation methodologies used for our pension assets. There have been no changes in the methodologies used at December 31, 2021 and 2020:


Common Stock:			Common stock is valued at the closing price reported on the common stock’s respective stock exchange and is classified within level 1 of the valuation hierarchy.

Fixed Income Securities:			Valued at the closing price reported on the active market on which the individual securities are traded and are classified within level 1 of the valuation hierarchy.

Money Market Fund:			These investments are public investment vehicles valued using the Net Asset Value (NAV).

Mutual Funds:			These investments are public investment vehicles valued using the Net Asset Value (NAV) provided by the administrator of the fund. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the pension plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The following table sets forth the value of the pension plan's assets as of December 31, 2021 and December 31, 2020:


	2021		2020
Investments measured at fair value:
Level 1
Common Stock	$	9,767	$	9,185
Fixed Income Securities	20,272		17,848
Total Investments measured at fair value	30,039		27,033

Investments measured at NAV:
Money Market Fund	1,098		915
Mutual Funds	48,267		48,992
Total Investments measured at NAV	49,365		49,907

Total Investments	$	79,404	$	76,940

We do not expect to make any contributions to our pension plan for 2022.

The following table summarizes the benefits and settlements expected to be paid by our pension plan in each of the next five years and in aggregate for the following five years. The expected payments are estimated based on the same assumptions used to measure the Company’s projected benefit obligation at December 31, 2021 and reflect the impact of expected future employee service.


2022			$6,427
2023			5,801
2024			5,627
2025			5,890
2026			6,026
2027-2031			26,543

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Legal Matters and Contingencies	12 Months Ended
Legal Matters and Contingencies	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Legal Matters and Contingencies	Legal Matters and Contingencies From time to time, the Company may receive an information request, subpoena or warrant from a government agency such as the Securities and Exchange Commission, Department of Justice, Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, the United States Food and Drug Administration, the Department of Labor, the Treasury Department or other federal and state agencies or foreign governments or government agencies. These information requests, subpoenas or warrants may or may not be routine inquiries, or may begin as routine inquiries and over time develop into enforcement actions of various types. Likewise, if we receive reports of alleged misconduct from employees and third parties, we investigate as appropriate. Manufacturers of medical devices have been the subject of various enforcement actions relating to interactions with health care providers domestically or internationally whereby companies are claimed to have provided health care providers with inappropriate incentives to purchase their products. Similarly, the Foreign Corrupt Practices Act ("FCPA") imposes obligations on manufacturers with respect to interactions with health care providers who may be considered government officials based on their affiliation with public hospitals. The FCPA also requires publicly listed manufacturers to maintain accurate books and records, and maintain internal accounting controls sufficient to provide assurance that transactions are accurately recorded, lawful and in accordance with management's authorization. The FCPA poses unique challenges both because manufacturers operate in foreign cultures in which conduct illegal under the FCPA may not be illegal in local jurisdictions, and because, in some cases, a United States manufacturer may face risks under the FCPA based on the conduct of third parties over whom the manufacturer may not have complete control. While CONMED has not experienced any material enforcement action to date, there can be no assurance that the Company will not be subject to a material enforcement action in the future, or that the Company will not incur costs including, in the form of fees for lawyers and other consultants, that are material to the Company’s results of operations in the course of responding to a future inquiry or investigation. Manufacturers of medical products may face exposure to significant product liability claims, as well as patent infringement and other claims incurred in the ordinary course of business. To date, we have not experienced any claims that have been material to our financial statements or financial condition, but any such claims arising in the future could have a material adverse effect on our business, results of operations or cash flows. We currently maintain commercial product liability insurance of $35 million per incident and $35 million in the aggregate annually, which we believe is adequate. This coverage is on a claims-made basis. There can be no assurance that claims will not exceed insurance coverage, that the carriers will be solvent or that such insurance will be available to us in the future at a reasonable cost. Our operations are subject, and in the past have been subject, to a number of environmental laws and regulations governing, among other things, air emissions; wastewater discharges; the use, handling and disposal of hazardous substances and wastes; soil and groundwater remediation and employee health and safety. Likewise, the operations of our suppliers and sterilizers are subject to similar environmental laws and regulations. In some jurisdictions, environmental requirements may be expected to become more stringent in the future. In the United States, certain environmental laws can impose liability for the entire cost of site restoration upon each of the parties that may have contributed to conditions at the site regardless of fault or the lawfulness of the party’s activities. While we do not believe that the present costs of environmental compliance and remediation are material, there can be no assurance that future compliance or remedial obligations would not have a material adverse effect on our financial condition, results of operations or cash flows. In 2014, the Company acquired EndoDynamix, Inc. The agreement governing the terms of the acquisition provides that, if various conditions are met, certain contingent payments relating to the first commercial sale of the products (the milestone payment), as well as royalties based on sales (the revenue based payments), are due to the seller. In 2016, we notified the seller that there was a need to redesign the product, and that, as a consequence, the first commercial sale had been delayed. Consequently, the payment of contingent milestone and revenue-based payments were delayed. On January 18, 2017, the seller provided notice (the "Notice") seeking $12.7 million under a liquidated damages clause, which essentially represents the seller's view as to the sum of the projected contingent milestone and revenue-based payments on an accelerated basis. CONMED responded to the Notice denying that there was any basis for acceleration of the payments due under the acquisition agreement. On February 22, 2017, the representative of the former shareholders of EndoDynamix filed a complaint in Delaware Chancery Court claiming breach of contract with respect to the duty to commercialize the product and seeking the contingent payments on an accelerated basis. We believe that there was a substantive contractual basis to support the Company's decision to redesign the product, such that there was no legitimate basis for seeking the liquidated damages. In the third quarter of 2018, the Company decided to halt the development of the EndoDynamix clip applier and recorded a charge to write off assets and released a previously accrued contingent consideration liability. In court filings the Plaintiffs claim to seek liquidated damages, as well as additional damages up to $24.8 million. A non-jury trial in the Delaware Chancery Court commenced on March 18, 2021, and testimony concluded on April 7, 2021. The parties have submitted post-trial briefs, the Court heard oral arguments at a hearing on September 16, 2021 and requested additional briefs which are expected to be filed at the end of February 2022. The Court will thereafter issue a ruling. The Company has not recorded any expense related to potential damages in connection with this matter because the Company does not believe any potential loss is probable. We expect to defend the claims asserted by the sellers of EndoDynamix, although there can be no assurance that we will prevail in the trial and/or any resulting appeals. CONMED is defending two Georgia State Court actions. The first in Cobb County was filed by various employees, former employees, contract workers and others against CONMED, and against a contract sterilizer. The second action in Douglas County is against CONMED’s landlord and other allegedly related entities. Plaintiffs in the lawsuits allege personal injury and related claims purportedly arising from or relating to exposure to Ethylene Oxide, a chemical used to sterilize certain products. CONMED is defending the claims asserted directly against it and is providing indemnification for certain other defendants based on contractual provisions. CONMED has submitted all of the claims for insurance coverage. One insurer is providing coverage for certain of the claims asserted directly against the Company. CONMED is currently in litigation with one of the other insurers regarding coverage for certain of the indemnification claims. Both actions are in their early stages and discovery has not yet started. The Company’s motion to dismiss in the Cobb County action was heard on January 10, 2022. CONMED believes it has strong defenses to the claims and will vigorously defend itself and all parties it is indemnifying. As with any litigation, there are risks, including the risk that CONMED may not prevail with respect to the defense of the underlying claims, or with respect to securing adequate insurance coverage for the indemnification claims. The Company is unable to estimate any range of possible loss at this time, and has not recorded any expense related to potential damages in connection with this matter because the Company does not believe any potential loss is probable. From time to time, we are also subject to negligence and other claims arising out of the ordinary conduct of our business, including, for example, accidents our employees may experience within the course of their employment or otherwise. We are currently defending one such claim, which we expect to be fully covered by insurance, involving potentially significant personal injuries. The Company is unable to estimate any range of possible loss at this time, and therefore has not recorded any liability related to potential damages in connection with this matter. We record reserves sufficient to cover probable and estimable losses associated with any such pending claims. We do not expect that the resolution of any pending claims, investigations or reports of alleged misconduct will have a material adverse effect on our financial condition, results of operations or cash flows. There can be no assurance, however, that future claims or investigations, or the costs associated with responding to such claims, investigations or reports of misconduct, especially claims and investigations not covered by insurance, will not have a material adverse effect on our financial condition, results of operations or cash flows.

Acquisition and Other Expense

12 Months Ended

Dec. 31, 2021

Acquisition and Other Expense [Abstract]

Acquisition and Other Expense

Acquisition and other expense for the year ended December 31, consists of the following:


	2021		2020		2019
Plant underutilization costs	$	—	$	6,586	$	—
Manufacturing consolidation costs	—		3,993		2,858
Acquisition and integration costs	—		2,820		1,335
Product rationalization costs - inventory	—		2,169		—
Restructuring costs	—		1,087		—


Acquisition and other expense included in cost of sales	$	—	$	16,655	$	4,193

Restructuring and related costs	$	414	$	4,782	$	—
Product rationalization costs - field inventory	—		2,095		—
Acquisition and integration costs	—		1,192		13,066


Acquisition and other expense included in selling and administrative expense	$	414	$	8,069	$	13,066

Debt refinancing costs included in other expense	$	1,127	$	—	$	3,904

During 2020, we recorded a $6.6 million charge to cost of sales related to plant underutilization due to abnormally low production as a result of decreased sales caused by the COVID-19 pandemic.

During 2020, we incurred $4.0 million in costs related to the consolidation of manufacturing operations which were charged to cost of sales. These costs included winding down operations at certain locations and moving production lines to other facilities. During 2019, we incurred $2.9 million in severance and other costs related to the consolidation of certain manufacturing operations which were charged to cost of sales.

During 2020, we recognized costs for inventory step-up adjustments and other costs related to a previous acquisition of $2.8 million. During 2019, we incurred $1.3 million in costs for inventory adjustments and other costs associated with the acquisition of Buffalo Filter as further described in Note 2. These costs were charged to cost of sales.

During 2020, we performed an analysis of our product lines and determined certain catalog numbers, principally related to capital equipment, would be discontinued and consolidated into existing product offerings. We consequently recorded a $2.2 million charge to cost of sales to write-off inventory of the discontinued products. In addition, we incurred $2.1 million in costs related to the write-off of field inventory used for customer demonstration and evaluation of the discontinued products which we charged to selling and administrative expense.

During 2020, we incurred $1.1 million in restructuring costs related to a voluntary separation arrangement with employees as a result of the COVID-19 pandemic which were charged to cost of sales based on the job function of the affected employees. Substantially all of the costs associated with the voluntary separation arrangement were paid during 2020.

During 2021 and 2020, we recorded charges of $0.4 million and $3.8 million, respectively, related to the restructuring of our sales force which consisted primarily of termination payments to Orthopedic distributors made in exchange for ongoing assistance to transition to employee-based sales representatives and severance that was charged to selling and administrative expense.

During 2020, we recorded $0.9 million in restructuring charges principally related to a voluntary separation arrangement with employees as a result of the COVID-19 pandemic which were charged to selling and administrative expense based on the nature of the costs and function of the affected employees. Substantially all of the costs associated with the voluntary separation arrangement were paid during 2020.

During 2020 and 2019, we incurred $1.2 million and $13.1 million, respectively, in costs associated with the February 11, 2019 acquisition of Buffalo Filter as further described in Note 2 that were included in selling and administrative expense. These costs include investment banking fees, consulting fees, legal fees, severance and integration related costs.

During 2021, we recorded $1.1 million related to a loss on early extinguishment and third party fees associated with the seventh amended and restated senior credit agreement as further described in Note 7. These costs were included in other expense. During 2019, we incurred a $3.6 million charge related to commitment fees paid to certain of our lenders, which provided a financing commitment for the Buffalo Filter acquisition and recorded a loss on the early extinguishment of debt of $0.3 million in conjunction with the sixth amended and restated senior credit agreement.

Guarantees

12 Months Ended

Dec. 31, 2021

Guarantees [Abstract]

Guarantees

We provide warranties on certain of our products at the time of sale and sell extended warranties. The standard warranty period for our capital equipment is generally one year and our extended warranties typically vary from one to three years. Liability under service and warranty policies is based upon a review of historical warranty and service claim experience. Adjustments are made to accruals as claim data and historical experience warrant.

Changes in the carrying amount of standard warranties for the year ended December 31, are as follows:


	2021		2020		2019
Balance as of January 1,	$	1,826	$	2,186	$	1,585

Provision for warranties	1,458		783		1,699
Claims made	(940)		(1,143)		(1,098)

Balance as of December 31,	$	2,344	$	1,826	$	2,186

Costs associated with extended warranty repairs are recorded as incurred and amounted to $6.8 million, $6.1 million and $5.3 million for the years ended December 31, 2021, 2020 and 2019 respectively.

Fair Value Measurement

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurement

We enter into derivative instruments for risk management purposes only. We operate internationally and, in the normal course of business, are exposed to fluctuations in interest rates, foreign exchange rates and commodity prices. These fluctuations can increase the costs of financing, investing and operating the business. We use forward contracts, a type of derivative instrument, to manage certain foreign currency exposures.

By nature, all financial instruments involve market and credit risks. We enter into forward contracts with major investment grade financial institutions and have policies to monitor the credit risk of those counterparties. While there can be no assurance, we do not anticipate any material non-performance by any of these counterparties.

Foreign Currency Forward Contracts. We hedge forecasted intercompany sales denominated in foreign currencies through the use of forward contracts. We account for these forward contracts as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in current earnings but are included in accumulated other comprehensive loss. These changes in fair value will be recognized into earnings as a component of sales or cost of sales when the forecasted transaction occurs.

We also enter into forward contracts to exchange foreign currencies for United States dollars in order to hedge our currency transaction exposures. These forward contracts settle each month at month-end, at which time we enter into new forward contracts. We have not designated these forward contracts as hedges and have not applied hedge accounting to them.

The following table presents the notional contract amounts for forward contracts outstanding:


		As of
	FASB ASC Topic 815 Designation	December 31, 2021		December 31, 2020
Forward exchange contracts	Cash flow hedge	$	172,894	$	154,504
Forward exchange contracts	Non-designated	38,897		42,380

The remaining time to maturity as of December 31, 2021 is within two years for hedge designated foreign exchange contracts and approximately one month for non-hedge designated forward exchange contracts.

Statement of comprehensive income presentation

Derivatives designated as cash flow hedges

Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive income (loss) ("AOCI") and net earnings on our consolidated statements of comprehensive income and our consolidated balance sheets:


	Amount of Gain (Loss) Recognized in AOCI						Consolidated Statements of Comprehensive Income							Amount of Gain (Loss) Reclassified from AOCI
	Years Ended							Total Amount of Line Item Presented						Years Ended
Derivative Instrument	2021		2020		2019		Location of amount reclassified	2021		2020		2019		2021		2020		2019

Foreign exchange contracts	$	8,650	$	(7,111)	$	3,871	Net Sales	$	1,010,635	$	862,459	$	955,097	$	(5,421)	$	1,997	$	7,969
							Cost of Sales	442,599		402,159		430,382		1,411		(619)		638
Pre-tax gain (loss)	$	8,650	$	(7,111)	$	3,871								$	(4,010)	$	1,378	$	8,607
Tax expense (benefit)	2,090		(1,718)		935									(969)		333		2,079
Net gain (loss)	$	6,560	$	(5,393)	$	2,936								$	(3,041)	$	1,045	$	6,528

At December 31, 2021, $3.7 million of net unrealized gains on forward contracts accounted for as cash flow hedges, and included in accumulated other comprehensive loss, are expected to be recognized in earnings in the next twelve months.

Derivatives not designated as cash flow hedges

Net gains and losses from derivative instruments not accounted for as hedges offset by gains and losses on our intercompany receivables on our consolidated statements of comprehensive income were:


		Years Ended
Derivative Instrument	Location on Consolidated Statements of Comprehensive Income	2021		2020		2019

Net loss on currency forward contracts	Selling and administrative expense	$	(451)	$	(2,269)	$	(573)
Net gain (loss) on currency transaction exposures	Selling and administrative expense	$	(1,832)	$	646	$	(653)

Balance sheet presentation

We record these forward foreign exchange contracts at fair value. The following tables summarize the fair value for forward foreign exchange contracts outstanding at December 31, 2021 and 2020:


December 31, 2021	Location on Consolidated Balance Sheet	Asset Fair Value		Liabilities Fair Value		Net Fair Value
Derivatives designated as hedging instruments:
Foreign exchange contracts	Prepaid expenses and other current assets	$	5,331	$	(430)	$	4,901
Foreign exchange contracts	Other long-term liabilities	82		(161)		(79)
		$	5,413	$	(591)	$	4,822

Derivatives not designated as hedging instruments:
Foreign exchange contracts	Other current liabilities	38		(180)		(142)

Total derivatives		$	5,451	$	(771)	$	4,680


December 31, 2020	Location on Consolidated Balance Sheet	Asset Fair Value		Liabilities Fair Value		Net Fair Value
Derivatives designated as hedging instruments:
Foreign exchange contracts	Other current liabilities	$	1,500	$	(8,826)	$	(7,326)
Foreign exchange contracts	Other long-term liabilities	23		(535)		(512)
		$	1,523	$	(9,361)	$	(7,838)

Derivatives not designated as hedging instruments:
Foreign exchange contracts	Other current liabilities	25		(150)		(125)

Total derivatives		$	1,548	$	(9,511)	$	(7,963)

Our forward foreign exchange contracts are subject to a master netting agreement and qualify for netting in the consolidated balance sheets.

Fair Value Disclosure. FASB guidance defines fair value and establishes a framework for measuring fair value and related disclosure requirements. This guidance applies when fair value measurements are required or permitted. The guidance indicates, among other things, that a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. Fair value is defined based upon an exit price model.

Valuation Hierarchy. A valuation hierarchy was established for disclosure of the inputs to the valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from or corroborated by observable market data through correlation. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. There have been no significant changes in the assumptions.

Valuation Techniques. Assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2021 consist of forward foreign exchange contracts. The Company values its forward foreign exchange contracts

using quoted prices for similar assets. The most significant assumption is quoted currency rates. The value of the forward foreign exchange contract assets and liabilities were valued using Level 2 inputs and are listed in the table above.

The carrying amounts reported in our balance sheets for cash and cash equivalents, accounts receivable, accounts payable and variable long-term debt approximate fair value.

New Accounting Pronouncements	12 Months Ended
New Accounting Pronouncements	Dec. 31, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles	New Accounting Pronouncements Recently Issued Accounting Standards, Not Yet Adopted In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional guidance if certain criteria are met for entities that have contracts, hedging relationships, and other transactions that reference LIBOR or other reference rates expected to be discontinued as a result of reference rate reform. This ASU is effective as of March 12, 2020 through December 31, 2022. The Company has not adopted the ASU as of December 31, 2021. Our seventh amended and restated senior credit agreement includes language to address the change from LIBOR to an alternative base rate, therefore we do not believe reference rate reform will have a significant impact on our consolidated financial statements, however we will continue to monitor our transition away from LIBOR and the potential to elect to apply this guidance in our consolidated financial statements in the event that we are impacted by reference rate reform. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing certain separation models requiring separate accounting for embedded conversion features which will result in more convertible debt instruments accounted for as a single liability. The ASU eliminates certain settlement conditions that are required for equity classification to qualify for the derivative scope exception. The ASU addresses how convertible instruments are accounted for in the calculation of diluted earnings per share by using the if-converted method. The ASU is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company will adopt this standard on January 1, 2022 using the modified retrospective method. The adoption of this new guidance is estimated to result in an increase of approximately $22.6 million to long-term debt in the consolidated balance sheets, to reflect the full principal amount of the convertible notes outstanding net of issuance costs, a reduction of approximately $37.9 million to additional paid-in capital, net of estimated income tax effects, to remove the equity component separately recorded for the conversion features associated with the convertible notes, a decrease to deferred tax liabilities, net of approximately $5.5 million, and a cumulative-effect adjustment of approximately $20.8 million, net of estimated income tax effects, to the beginning balance of retained earnings as of January 1, 2022. The adoption of this new guidance is anticipated to reduce interest expense by approximately $10.4 million during the year ended December 31, 2022. Additionally, the modified retrospective approach will result in an increase in the dilutive share count as a result of calculating the impact of dilution from the Company's convertible notes using the if-converted method.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (c)

+ Details

Schedule II - Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2021

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Valuation and Qualifying Accounts

SCHEDULE II—Valuation and Qualifying Accounts

(In thousands)




			Additions
	Balance at Beginning of Period		Charged to Costs and Expenses
							Balance at End of Period
Description					Deductions
2021
Allowance for bad debts	$	3,876	$	2,305	$	(1,653)	$	4,528
Sales returns and
allowance	3,684		1,261		(504)		4,441
Deferred tax asset
valuation allowance	2,721		621		(2,556)		786


2020
Allowance for bad debts	$	2,786	$	1,611	$	(521)	$	3,876
Sales returns and
allowance	3,667		384		(367)		3,684
Deferred tax asset
valuation allowance	1,732		989		—		2,721


2019
Allowance for bad debts	$	2,660	$	852	$	(726)	$	2,786
Sales returns and
allowance	3,246		518		(97)		3,667
Deferred tax asset
valuation allowance	1,159		573		—		1,732

Operations and Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Principles of consolidation

The consolidated financial statements include the accounts of CONMED Corporation and its controlled subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Use of estimates

Cash and cash equivalents

We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.

Inventories

Inventories are valued at the lower of cost and net realizable value determined on the FIFO (first-in, first-out) cost method.

Property, plant and equipment

Property, plant and equipment are stated at cost and depreciated using the straight-line method over the following estimated useful lives:


			Building and improvements			12 to 40 years
			Leasehold improvements			Shorter of life of asset or life of lease
			Machinery and equipment			2 to 15 years

Lessee, Leases

Leases

Lessor, Leases

Goodwill and other intangible assets

Other long-lived assets

Translation of foreign currency financial statements

Foreign exchange and hedging activity

Income taxes

Revenue recognition

•Revenue is recognized when product is shipped at which point the performance obligation is satisfied and the customer obtains control of the product.

•We sell to a diversified base of customers around the world and, therefore, believe there is no material concentration of credit risk.

Earnings per share

Earnings per shareBasic earnings per share (“basic EPS”) is computed by dividing net income by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding resulting from employee stock options, restricted stock units, performance share units and stock appreciation rights during the period.

Stock-based compensation

New Accounting Pronouncements New Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Issued Accounting Standards, Not Yet Adopted In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional guidance if certain criteria are met for entities that have contracts, hedging relationships, and other transactions that reference LIBOR or other reference rates expected to be discontinued as a result of reference rate reform. This ASU is effective as of March 12, 2020 through December 31, 2022. The Company has not adopted the ASU as of December 31, 2021. Our seventh amended and restated senior credit agreement includes language to address the change from LIBOR to an alternative base rate, therefore we do not believe reference rate reform will have a significant impact on our consolidated financial statements, however we will continue to monitor our transition away from LIBOR and the potential to elect to apply this guidance in our consolidated financial statements in the event that we are impacted by reference rate reform. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing certain separation models requiring separate accounting for embedded conversion features which will result in more convertible debt instruments accounted for as a single liability. The ASU eliminates certain settlement conditions that are required for equity classification to qualify for the derivative scope exception. The ASU addresses how convertible instruments are accounted for in the calculation of diluted earnings per share by using the if-converted method. The ASU is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company will adopt this standard on January 1, 2022 using the modified retrospective method. The adoption of this new guidance is estimated to result in an increase of approximately $22.6 million to long-term debt in the consolidated balance sheets, to reflect the full principal amount of the convertible notes outstanding net of issuance costs, a reduction of approximately $37.9 million to additional paid-in capital, net of estimated income tax effects, to remove the equity component separately recorded for the conversion features associated with the convertible notes, a decrease to deferred tax liabilities, net of approximately $5.5 million, and a cumulative-effect adjustment of approximately $20.8 million, net of estimated income tax effects, to the beginning balance of retained earnings as of January 1, 2022. The adoption of this new guidance is anticipated to reduce interest expense by approximately $10.4 million during the year ended December 31, 2022. Additionally, the modified retrospective approach will result in an increase in the dilutive share count as a result of calculating the impact of dilution from the Company's convertible notes using the if-converted method.

Operations and Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of property plant and equipment useful life

Property, plant and equipment are stated at cost and depreciated using the straight-line method over the following estimated useful lives:


			Building and improvements			12 to 40 years
			Leasehold improvements			Shorter of life of asset or life of lease
			Machinery and equipment			2 to 15 years

Schedule of calculation of basic and diluted earnings per share

The following table sets forth the computation of basic and diluted earnings per share at December 31, 2021, 2020 and 2019, respectively:


	2021		2020		2019

Net income	$	62,542	$	9,517	$	28,620

Basic-weighted average shares outstanding	29,162		28,581		28,325

Effect of dilutive potential securities	3,054		883		1,170

Diluted-weighted average shares outstanding	32,216		29,464		29,495

Net income (per share)
Basic	$	2.14	$	0.33	$	1.01
Diluted	1.94		0.32		0.97

Schedule of accumulated other comprehensive loss

Accumulated other comprehensive loss consists of the following:


	Cash Flow Hedging Gain (Loss)		Pension Liability		Foreign Currency Translation Adjustments		Accumulated Other Comprehensive Loss

Balance, December 31, 2018	$	4,085	$	(31,718)	$	(28,104)	$	(55,737)

Other comprehensive income (loss) before reclassifications, net of tax	2,936		(2,158)		25		803
Amounts reclassified from accumulated other comprehensive income before tax(a)	(8,607)		2,881		—		(5,726)
Income tax	2,079		(696)		—		1,383

Net current-period other comprehensive income (loss)	(3,592)		27		25		(3,540)

Balance, December 31, 2019	$	493	$	(31,691)	$	(28,079)	$	(59,277)

Other comprehensive income (loss) before reclassifications, net of tax	(5,393)		(7,068)		6,963		(5,498)
Amounts reclassified from accumulated other comprehensive income (loss) before tax(a)	(1,378)		2,821		—		1,443
Income tax	333		(682)		—		(349)

Net current-period other comprehensive income (loss)	(6,438)		(4,929)		6,963		(4,404)

Balance, December 31, 2020	$	(5,945)	$	(36,620)	$	(21,116)	$	(63,681)

Other comprehensive income (loss) before reclassifications, net of tax	6,560		4,426		(7,072)		3,914
Amounts reclassified from accumulated other comprehensive income (loss) before tax(a)	4,010		3,327		—		7,337
Income tax	(969)		(804)		—		(1,773)

Net current-period other comprehensive income (loss)	9,601		6,949		(7,072)		9,478

Balance, December 31, 2021	$	3,656	$	(29,671)	$	(28,188)	$	(54,203)

Business Acqusition Business Acquisition (Tables)

12 Months Ended

Dec. 31, 2021

Business Combinations [Abstract]

Business Acquisition, Pro Forma Information


	2019
Net sales	$	960,115
Net income	44,361

Inventories (Tables)

12 Months Ended

Dec. 31, 2021

Inventory Disclosure [Abstract]

Schedule of inventory

Inventories consist of the following at December 31:


	2021		2020
Raw materials	$	83,386	$	71,807
Work in process	17,449		15,864
Finished goods	130,809		107,197
	$	231,644	$	194,868

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Abstract]

Schedule of property, plant and equipment

Property, plant and equipment consist of the following at December 31:


	2021		2020
Land	$	4,027	$	4,027
Building and improvements	95,518		93,886
Machinery and equipment	256,478		243,810
Construction in progress	16,601		15,680
	372,624		357,403
Less: Accumulated depreciation	(263,761)		(245,996)
	$	108,863	$	111,407

Leases (Tables)

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Lease, Cost [Table Text Block]

Lease costs for the year ended December 31, consist of the following:


	2021		2020		2019
Operating lease cost:
Straight-line lease cost	$	7,720	$	7,255	$	7,780
Right-of-use asset impairment cost	—		—		312
Total operating lease cost	7,720		7,255		8,092
Finance lease cost:
Depreciation	389		355		238
Interest on lease liabilities	30		33		27
Total finance lease cost	419		388		265
Total lease cost	$	8,139	$	7,643	$	8,357

Supplemental Balance Sheet Information Related to Leases [Table Text Block]

Supplemental balance sheet information related to leases as of December 31, is as follows:


	2021			2020
Operating leases
Other assets	$	19,425		$	21,659

Other current liabilities	$	7,162		$	7,469
Other long-term liabilities	12,726			14,756
Total operating lease liabilities	$	19,888		$	22,225

Finance leases
Property, plant and equipment, gross	$	1,984		$	1,762
Accumulated depreciation	(1,145)			(825)
Property, plant and equipment, net	$	839		$	937

Current portion of long-term debt	$	324		$	197
Long-term debt	240			390
Total finance lease liabilities	$	564		$	587


Weighted average remaining lease term (in years)
Operating leases	3.90 years			3.76 years
Finance leases	3.05 years			3.22 years

Weighted average discount rate
Operating leases	5.02		%	5.00		%
Finance leases	4.47		%	4.93		%

Supplemental Cash Flow Information Related to Leases [Table Text Block]

Supplemental cash flow information related to leases for the year ended December 31, was as follows:


	2021		2020		2019

Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	7,791	$	7,535	$	8,459
Financing cash flows from finance leases	287		373		380

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	4,704		4,242		12,800
Finance leases	305		76		563

Operating Lease, Liability, Maturity

Maturities of lease liabilities as of December 31, 2021 are as follows:


	Finance Lease		Operating Lease

2022	$	324	$	7,162
2023	188		5,830
2024	62		4,555
2025	8		1,637
2026	5		795
Thereafter	1		2,174
Total lease payments	588		22,153

Less imputed interest	(24)		(2,265)

Total lease liabilities	$	564	$	19,888

Finance Lease, Liability, Maturity

Maturities of lease liabilities as of December 31, 2021 are as follows:


	Finance Lease		Operating Lease

2022	$	324	$	7,162
2023	188		5,830
2024	62		4,555
2025	8		1,637
2026	5		795
Thereafter	1		2,174
Total lease payments	588		22,153

Less imputed interest	(24)		(2,265)

Total lease liabilities	$	564	$	19,888

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The changes in the net carrying amount of goodwill for the years ended December 31, are as follows:


	2021		2020
Balance as of January 1,	$	618,440	$	618,042



Goodwill adjustment resulting from business combinations	—		(1,009)

Foreign currency translation	(912)		1,407

Balance as of December 31,	$	617,528	$	618,440

Schedule of Finite-Lived Intangible Assets

Other intangible assets consist of the following:


	December 31, 2021					December 31, 2020
	Weighted Average Amortization Period (Years)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Intangible assets with definite lives:	22

Customer and distributor relationships	24	$	342,452	$	(152,934)	$	342,639	$	(134,555)

Sales representation, marketing and promotional rights	25	149,376		(60,000)		149,376		(54,000)

Patents and other intangible assets	16	76,392		(50,890)		73,516		(48,882)

Developed technology	16	106,604		(26,495)		106,604		(19,705)

Intangible assets with indefinite lives:

Trademarks and tradenames		86,544		—		86,544		—

		$	761,368	$	(290,319)	$	758,679	$	(257,142)

Schedule of Indefinite-Lived Intangible Assets

Other intangible assets consist of the following:


	December 31, 2021					December 31, 2020
	Weighted Average Amortization Period (Years)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Intangible assets with definite lives:	22

Customer and distributor relationships	24	$	342,452	$	(152,934)	$	342,639	$	(134,555)

Sales representation, marketing and promotional rights	25	149,376		(60,000)		149,376		(54,000)

Patents and other intangible assets	16	76,392		(50,890)		73,516		(48,882)

Developed technology	16	106,604		(26,495)		106,604		(19,705)

Intangible assets with indefinite lives:

Trademarks and tradenames		86,544		—		86,544		—

		$	761,368	$	(290,319)	$	758,679	$	(257,142)

Schedule of Estimated Amortization Expense

The estimated amortization expense related to intangible assets at December 31, 2021 and for each of the five succeeding years is as follows:


	Amortization included in expense		Amortization recorded as a reduction of revenue		Total
2022	$	26,397	$	6,000	$	32,397
2023	25,665		6,000		31,665
2024	24,947		6,000		30,947
2025	25,140		6,000		31,140
2026	24,651		6,000		30,651

Long Term Debt (Tables)

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Long-term debt consists of the following at December 31:


	2021		2020
Revolving line of credit	$	140,000	$	207,000
Term loan, net of deferred debt issuance costs of $1,373 and $1,668 in 2021 and 2020, respectively	226,196		240,145
2.625% convertible notes, net of deferred debt issuance costs of $3,700 and $5,475 in 2021 and 2020, respectively, and unamortized discount of $23,404 and $33,620 in 2021 and 2020, respectively	317,896		305,904
Financing leases	564		587
Total debt	684,656		753,636
Less: Current portion	12,249		18,415
Total long-term debt	$	672,407	$	735,221

Schedule of Maturities of Long-term Debt

The scheduled maturities of long-term debt outstanding at December 31, 2021 are as follows:


2022	$	11,925
2023	14,906
2024	365,869
2025	23,850
2026	296,019

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644

+ Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Schedule of Provision for Income Taxes

The provision (benefit) for income taxes for the years ended December 31, 2021, 2020 and 2019 consists of the following:


	2021		2020		2019
Current tax expense (benefit):
Federal	$	(97)	$	(729)	$	96
State	609		86		444
Foreign	7,046		6,963		8,375
	7,558		6,320		8,915
Deferred income tax expense (benefit):
Federal	3,466		(12,253)		(3,970)
State	1,449		(1,173)		(938)
Foreign	(1,910)		(808)		(1,402)
	3,005		(14,234)		(6,310)

Provision (benefit) for income taxes	$	10,563	$	(7,914)	$	2,605

Schedule of Effective Income Tax Rate Reconciliation

A reconciliation between income taxes computed at the statutory federal rate and the provision (benefit) for income taxes for the years ended December 31, 2021, 2020 and 2019 follows:


	2021		2020		2019
Tax provision at statutory rate based on income before income taxes	21.0	%	21.0	%	21.0	%

Stock-based compensation	(9.4)		(267.7)		(15.4)

Federal research credit	(2.3)		(124.2)		(4.0)

Valuation allowance	(2.2)		49.7		1.9

US tax on worldwide earnings at different rates	(0.4)		(123.7)		7.9

Settlement of taxing authority examinations	—		(122.9)		(7.7)

Tax treaty protocols	—		—		(2.9)

Non deductible/non-taxable items	0.8		28.6		2.8

Foreign income taxes	3.1		79.9		4.5

State income taxes, net of federal tax benefit	3.7		(24.5)		0.3







Other, net	0.1		(10.1)		(0.1)

	14.4	%	(493.9)	%	8.3	%

Schedule of Deferred Tax Assets and Liabilities

The tax effects of the significant temporary differences which comprise the deferred income tax assets and liabilities at December 31, 2021 and 2020 are as follows:


	2021		2020
Assets:
Inventory	$	4,694	$	4,649
Net operating losses	18,383		22,197
Capitalized research and development	4,173		5,187
Deferred compensation	2,563		2,240
Accounts receivable	3,147		2,784
Compensation and benefits	6,583		7,540
Accrued pension	3,930		5,348
Research and development credit	15,542		13,540

Convertible notes hedge	4,869		6,999
Lease liabilities	3,573		4,452
Other	5,741		6,793
Less: valuation allowances	(786)		(2,721)
	72,412		79,008

Liabilities:
Goodwill and intangible assets	106,065		104,119
Depreciation	2,546		2,512
State taxes	11,833		9,614
Unremitted foreign earnings	2,449		2,423
Convertible notes debt discount	4,915		7,060
Lease right-of-use assets	3,484		4,313

	131,292		130,041

Net liability	$	(58,880)	$	(51,033)

Schedule of Income before Income Tax

Income before income taxes consists of the following U.S. and foreign income:


	2021		2020		2019
U.S. income	$	45,260	$	(16,026)	$	5,332
Foreign income	27,845		17,629		25,893
Total income	$	73,105	$	1,603	$	31,225

Schedule of Unrecognized Tax Benefits Rollforward

The following table summarizes the activity related to our unrecognized tax benefits for the years ending December 31,:


	2021		2020		2019
Balance as of January 1,	$	200	$	2,170	$	3,073



Increases for positions taken in current periods	—		—		1,650

Decreases in unrecorded tax positions related to settlement with the taxing authorities	—		(1,970)		(2,404)

Decreases in unrecorded tax positions related to lapse of statute of limitations	—		—		(149)

Balance as of December 31,	$	200	$	200	$	2,170

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2021

Stock Options and Stock Appreciation Rights (SARs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Valuation Assumptions

The following table illustrates the assumptions used in estimating fair value in the years ended December 31, 2021, 2020 and 2019:


	2021			2020			2019
Grant date fair value of stock options and SARs	$	42.47		$	22.62		$	20.59
Expected stock price volatility	39.27		%	26.89		%	26.59		%
Risk-free interest rate	0.81		%	0.89		%	2.58		%
Expected annual dividend yield	0.64		%	0.82		%	1.08		%
Expected life of options & SARs (years)	5.5			5.5			5.6

Schedule of stock option and SAR activity

The following table illustrates the stock option and SAR activity for the year ended December 31, 2021:


	Number of Shares (in 000’s)	Weighted- Average Exercise Price
Outstanding at December 31, 2020	3,336	$	66.76

Granted	701	$	123.21
Forfeited	(177)	$	82.35
Exercised	(596)	$	51.59

Outstanding at December 31, 2021	3,264	$	80.79
Exercisable at December 31, 2021	1,284	$	59.40
Stock options & SARs expected to vest	1,980	$	94.67

Restricted Stock Units (RSUs) and Performance Share Units (PSUs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of RSU and PSU activity

The following table illustrates the RSU activity for the year ended December 31, 2021:


	Number of Shares (in 000’s)	Weighted- Average Grant-Date Fair Value
Outstanding at December 31, 2020	61	$	77.03

Granted	21	$	129.94
Vested	(30)	$	73.11
Forfeited	(1)	$	55.96

Outstanding at December 31, 2021	51	$	101.55

Revenues (Tables)

12 Months Ended

Dec. 31, 2021

Revenues [Abstract]

Disaggregation of Revenue

The following tables present revenue disaggregated by product line and timing of revenue recognition for the years ended December 31, 2021, 2020 and 2019:


	2021
	Orthopedic Surgery		General Surgery		Total
Timing of Revenue Recognition
Goods transferred at a point in time	$	398,963	$	567,244	$	966,207
Services transferred over time	39,461		4,967		44,428
Total sales from contracts with customers	$	438,424	$	572,211	$	1,010,635


	2020
	Orthopedic Surgery		General Surgery		Total
Timing of Revenue Recognition
Goods transferred at a point in time	$	340,318	$	484,147	$	824,465
Services transferred over time	34,387		3,607		37,994
Total sales from contracts with customers	$	374,705	$	487,754	$	862,459


	2019
	Orthopedic Surgery		General Surgery		Total
Timing of Revenue Recognition
Goods transferred at a point in time	$	426,893	$	489,313	$	916,206
Services transferred over time	36,429		2,462		38,891
Total sales from contracts with customers	$	463,322	$	491,775	$	955,097

Contract with Customer, Asset and Liability

Contract liability balances related to the sale of extended warranties to customers are as follows:


	December 31, 2021		December 31, 2020

Contract Liability	$	16,760	$	13,666

Business Segments and Geographic Areas (Tables)

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Revenue from External Customers by Geographic Areas and Product Line

These product lines' net sales and primary geographic market where the products are sold, are as follows for the years ended December 31, 2021, 2020 and 2019:


	2021
	Orthopedic Surgery		General Surgery		Total
Primary Geographic Markets
United States	$	158,553	$	393,980	$	552,533
Europe, Middle East & Africa	108,457		81,238		189,695
Asia Pacific	107,590		63,628		171,218
Americas (excluding the United States)	63,824		33,365		97,189
Total sales from contracts with customers	$	438,424	$	572,211	$	1,010,635


	2020
	Orthopedic Surgery		General Surgery		Total
Primary Geographic Markets
United States	$	139,715	$	342,349	$	482,064
Europe, Middle East & Africa	90,998		70,086		161,084
Asia Pacific	93,636		46,961		140,597
Americas (excluding the United States)	50,356		28,358		78,714
Total sales from contracts with customers	$	374,705	$	487,754	$	862,459


	2019
	Orthopedic Surgery		General Surgery		Total
Primary Geographic Markets
United States	$	179,419	$	337,246	$	516,665
Europe, Middle East & Africa	118,301		64,248		182,549
Asia Pacific	101,333		59,277		160,610
Americas (excluding the United States)	64,269		31,004		95,273
Total sales from contracts with customers	$	463,322	$	491,775	$	955,097

Employee Benefit Plans (Tables)

12 Months Ended

Dec. 31, 2021

Retirement Benefits [Abstract]

Schedule of reconciliation of the projected benefit obligation, plan assets and funded status of the pension plan

The following table provides a reconciliation of the projected benefit obligation, plan assets and funded status of the pension plan at December 31:


	2021		2020
Accumulated benefit obligation	$	95,508	$	101,242

Change in benefit obligation
Projected benefit obligation at beginning of year	$	101,242	$	92,052
Service cost	991		717
Interest cost	1,803		2,555
Actuarial loss (gain)	(3,427)		10,963
Benefits paid	(2,703)		(1,933)
Settlements	(2,398)		(3,112)
Projected benefit obligation at end of year	$	95,508	$	101,242

Change in plan assets
Fair value of plan assets at beginning of year	$	76,940	$	75,321
Actual gain on plan assets	7,565		6,664
Benefits paid	(2,703)		(1,933)
Settlements	(2,398)		(3,112)
Fair value of plan assets at end of year	$	79,404	$	76,940

Funded status	$	(16,104)	$	(24,302)

Schedule of amounts recognized in the consolidated balance sheets

Amounts recognized in the consolidated balance sheets consist of the following at December 31,:


	2021		2020
Other long-term liabilities	$	(16,104)	$	(24,302)
Accumulated other comprehensive loss	(39,122)		(48,285)

Schedule of actuarial assumptions used

The following actuarial assumptions were used to determine our accumulated and projected benefit obligations as of December 31,:


	2021		2020
Discount rate	2.81	%	2.44	%

The following actuarial assumptions were used to determine our net periodic pension benefit cost for the years ended December 31,:


	2021		2020		2019
Discount rate on benefit obligation	2.44	%	3.33	%	4.37	%
Effective rate for interest on benefit obligation	1.83	%	2.88	%	4.01	%
Expected return on plan assets	7.00	%	7.00	%	7.50	%

Schedule of plan assets and benefit obligations recognized in other comprehensive income

Other changes in plan assets and benefit obligations recognized in other comprehensive income in 2021 and 2020 are as follows:


	2021		2020
Current year actuarial loss (gain)	$	5,836	$	(9,320)
Amortization of actuarial loss	3,327		2,821
Total recognized in other comprehensive income (loss)	$	9,163	$	(6,499)

Schedule of net benefit cost

Net periodic pension cost for the years ended December 31, consists of the following:


	2021		2020		2019
Service cost	$	991	$	717	$	1,010
Interest cost on projected benefit obligation	1,803		2,555		3,130
Expected return on plan assets	(5,155)		(5,021)		(4,725)
Amortization of loss	3,327		2,821		2,881

Net periodic pension cost	$	966	$	1,072	$	2,296

Schedule of allocation of plan assets

The allocation of plan assets by category is as follows at December 31,:


	Percentage of Pension Plan Assets				Target Allocation
	2021		2020		2022
Equity securities	73	%	76	%	75	%
Debt securities	27	%	24	%	25	%
Total	100	%	100	%	100	%

The following table sets forth the value of the pension plan's assets as of December 31, 2021 and December 31, 2020:


	2021		2020
Investments measured at fair value:
Level 1
Common Stock	$	9,767	$	9,185
Fixed Income Securities	20,272		17,848
Total Investments measured at fair value	30,039		27,033

Investments measured at NAV:
Money Market Fund	1,098		915
Mutual Funds	48,267		48,992
Total Investments measured at NAV	49,365		49,907

Total Investments	$	79,404	$	76,940

Schedule of expected benefit payments


2022			$6,427
2023			5,801
2024			5,627
2025			5,890
2026			6,026
2027-2031			26,543

Acquisition and Other Expense (Tables)

12 Months Ended

Dec. 31, 2021

Acquisition and Other Expense [Abstract]

Schedule of Acquisition and Other Operating Expense

Acquisition and other expense for the year ended December 31, consists of the following:


	2021		2020		2019
Plant underutilization costs	$	—	$	6,586	$	—
Manufacturing consolidation costs	—		3,993		2,858
Acquisition and integration costs	—		2,820		1,335
Product rationalization costs - inventory	—		2,169		—
Restructuring costs	—		1,087		—


Acquisition and other expense included in cost of sales	$	—	$	16,655	$	4,193

Restructuring and related costs	$	414	$	4,782	$	—
Product rationalization costs - field inventory	—		2,095		—
Acquisition and integration costs	—		1,192		13,066


Acquisition and other expense included in selling and administrative expense	$	414	$	8,069	$	13,066

Debt refinancing costs included in other expense	$	1,127	$	—	$	3,904

Guarantees (Tables)

12 Months Ended

Dec. 31, 2021

Guarantees [Abstract]

Changes in the carrying amount of service and product warranties

Changes in the carrying amount of standard warranties for the year ended December 31, are as follows:


	2021		2020		2019
Balance as of January 1,	$	1,826	$	2,186	$	1,585

Provision for warranties	1,458		783		1,699
Claims made	(940)		(1,143)		(1,098)

Balance as of December 31,	$	2,344	$	1,826	$	2,186

Fair Value Measurement (Tables)

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]

The following table presents the notional contract amounts for forward contracts outstanding:


		As of
	FASB ASC Topic 815 Designation	December 31, 2021		December 31, 2020
Forward exchange contracts	Cash flow hedge	$	172,894	$	154,504
Forward exchange contracts	Non-designated	38,897		42,380

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]


	Amount of Gain (Loss) Recognized in AOCI						Consolidated Statements of Comprehensive Income							Amount of Gain (Loss) Reclassified from AOCI
	Years Ended							Total Amount of Line Item Presented						Years Ended
Derivative Instrument	2021		2020		2019		Location of amount reclassified	2021		2020		2019		2021		2020		2019

Foreign exchange contracts	$	8,650	$	(7,111)	$	3,871	Net Sales	$	1,010,635	$	862,459	$	955,097	$	(5,421)	$	1,997	$	7,969
							Cost of Sales	442,599		402,159		430,382		1,411		(619)		638
Pre-tax gain (loss)	$	8,650	$	(7,111)	$	3,871								$	(4,010)	$	1,378	$	8,607
Tax expense (benefit)	2,090		(1,718)		935									(969)		333		2,079
Net gain (loss)	$	6,560	$	(5,393)	$	2,936								$	(3,041)	$	1,045	$	6,528

Derivatives Not Designated as Hedging Instruments [Table Text Block]

Net gains and losses from derivative instruments not accounted for as hedges offset by gains and losses on our intercompany receivables on our consolidated statements of comprehensive income were:


		Years Ended
Derivative Instrument	Location on Consolidated Statements of Comprehensive Income	2021		2020		2019

Net loss on currency forward contracts	Selling and administrative expense	$	(451)	$	(2,269)	$	(573)
Net gain (loss) on currency transaction exposures	Selling and administrative expense	$	(1,832)	$	646	$	(653)

Schedule of fair value for forward foreign exchange contracts

We record these forward foreign exchange contracts at fair value. The following tables summarize the fair value for forward foreign exchange contracts outstanding at December 31, 2021 and 2020:


December 31, 2021	Location on Consolidated Balance Sheet	Asset Fair Value		Liabilities Fair Value		Net Fair Value
Derivatives designated as hedging instruments:
Foreign exchange contracts	Prepaid expenses and other current assets	$	5,331	$	(430)	$	4,901
Foreign exchange contracts	Other long-term liabilities	82		(161)		(79)
		$	5,413	$	(591)	$	4,822

Derivatives not designated as hedging instruments:
Foreign exchange contracts	Other current liabilities	38		(180)		(142)

Total derivatives		$	5,451	$	(771)	$	4,680


December 31, 2020	Location on Consolidated Balance Sheet	Asset Fair Value		Liabilities Fair Value		Net Fair Value
Derivatives designated as hedging instruments:
Foreign exchange contracts	Other current liabilities	$	1,500	$	(8,826)	$	(7,326)
Foreign exchange contracts	Other long-term liabilities	23		(535)		(512)
		$	1,523	$	(9,361)	$	(7,838)

Derivatives not designated as hedging instruments:
Foreign exchange contracts	Other current liabilities	25		(150)		(125)

Total derivatives		$	1,548	$	(9,511)	$	(7,963)

Operations and Significant Accounting Policies (Property, Plant and Equipment) (Details)	12 Months Ended
	Dec. 31, 2021
Building and improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life, average (in years)	12 years
Building and improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life, average (in years)	40 years
Machinery and equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life, average (in years)	2 years
Machinery and equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life, average (in years)	15 years

Operations and Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Jan. 29, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operations and Significant Accounting Policies [Line Items]
Lessee, Operating Lease, Termination Option Term		1 year
Selling and administrative expense		$ 414,754	$ 373,817	$ 400,141
Other Noncurrent Assets
Other Assets, Noncurrent [Abstract]
Field inventory		42,500	43,300
Shipping and Handling [Member]
Operations and Significant Accounting Policies [Line Items]
Selling and administrative expense		$ 17,000	$ 14,600	$ 15,400
Minimum [Member]
Operations and Significant Accounting Policies [Line Items]
Remaining Lease Term		1 year
Maximum [Member]
Operations and Significant Accounting Policies [Line Items]
Remaining Lease Term		10 years
Lessee, Operating Lease, Renewal Term		5 years
2.625 Percent Convertible Notes Due 2024 [Member] \| Convertible Notes Payable [Member]
Operations and Significant Accounting Policies [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.625%
Debt Instrument, Convertible, Conversion Price	$ 88.80
2.625 Percent Convertible Notes Due 2024 [Member] \| Convertible Notes Payable [Member] \| Warrant
Operations and Significant Accounting Policies [Line Items]
Option Indexed to Issuer's Equity, Strike Price	$ 114.92

Operations and Significant Accounting Policies (Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings per share:
Net income	$ 62,542	$ 9,517	$ 28,620
Basic-weighted average shares outstanding (in shares)	29,162	28,581	28,325
Effect of dilutive potential securities (in shares)	3,054	883	1,170
Diluted-weighted average shares outstanding (in shares)	32,216	29,464	29,495
Basic EPS (in dollars per share)	$ 2.14	$ 0.33	$ 1.01
Diluted EPS (in dollars per share)	$ 1.94	$ 0.32	$ 0.97
Shares excluded from computation of earnings per share	600	1,400	700
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities	1,300
Incremental Common Shares Attributable to Dilutive Effect of Warrants	500

Operations and Significant Accounting Policies (Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated other comprehensive income (loss), beginning of the period	$ (63,681)
Other Comprehensive Income (Loss), Net of Income Tax	9,478	$ (4,404)	$ (3,540)
Accumulated other comprehensive income (loss), end of the period	(54,203)	(63,681)
Accumulated Other Comprehensive Loss [Member]
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated other comprehensive income (loss), beginning of the period	(63,681)	(59,277)	(55,737)
Other comprehensive income (loss) before reclassifications, net of tax	3,914	(5,498)	803
Amounts reclassified from accumulated other comprehensive income (loss) before tax	7,337	1,443	(5,726)
Reclassification from AOCI, Current Period, Tax	(1,773)	(349)	1,383
Other Comprehensive Income (Loss), Net of Income Tax	9,478	(4,404)	(3,540)
Accumulated other comprehensive income (loss), end of the period	(54,203)	(63,681)	(59,277)
Cash Flow Hedging Gain (Loss) [Member]
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated other comprehensive income (loss), beginning of the period	(5,945)	493	4,085
Other comprehensive income (loss) before reclassifications, net of tax	6,560	(5,393)	2,936
Amounts reclassified from accumulated other comprehensive income (loss) before tax	4,010	(1,378)	(8,607)
Reclassification from AOCI, Current Period, Tax	(969)	333	2,079
Other Comprehensive Income (Loss), Net of Income Tax	9,601	(6,438)	(3,592)
Accumulated other comprehensive income (loss), end of the period	3,656	(5,945)	493
Pension Liability [Member]
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated other comprehensive income (loss), beginning of the period	(36,620)	(31,691)	(31,718)
Other comprehensive income (loss) before reclassifications, net of tax	4,426	(7,068)	(2,158)
Amounts reclassified from accumulated other comprehensive income (loss) before tax	3,327	2,821	2,881
Reclassification from AOCI, Current Period, Tax	(804)	(682)	(696)
Other Comprehensive Income (Loss), Net of Income Tax	6,949	(4,929)	27
Accumulated other comprehensive income (loss), end of the period	(29,671)	(36,620)	(31,691)
Cumulative Translation Adjustment [Member]
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated other comprehensive income (loss), beginning of the period	(21,116)	(28,079)	(28,104)
Other comprehensive income (loss) before reclassifications, net of tax	(7,072)	6,963	25
Amounts reclassified from accumulated other comprehensive income (loss) before tax	0	0	0
Reclassification from AOCI, Current Period, Tax	0	0	0
Other Comprehensive Income (Loss), Net of Income Tax	(7,072)	6,963	25
Accumulated other comprehensive income (loss), end of the period	$ (28,188)	$ (21,116)	$ (28,079)

Business Acqusition Business Acquisition (Details) - USD ($) $ in Thousands		12 Months Ended
	Feb. 11, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Payments to acquire business	$ 365,000
Revenues		$ 1,010,635	$ 862,459	$ 955,097
Pro Forma Information [Abstract]
Business Acquisition, Pro Forma Revenue				960,115
Business Acquisition, Pro Forma Net Income (Loss)				44,361
Buffalo Filter LLC [Member]
Business Acquisition [Line Items]
Revenues				$ 49,600

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 83,386	$ 71,807
Work in process	17,449	15,864
Finished goods	130,809	107,197
Total inventory	$ 231,644	$ 194,868

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 372,624	$ 357,403
Less: Accumulated depreciation	(263,761)	(245,996)
Total property, plant and equipment	108,863	111,407
Capitalized Computer Software, Gross	49,100	50,300
Capitalized Computer Software, Accumulated Amortization	(45,300)	(42,900)
Capitalized Computer Software, Amortization	3,300	4,700	$ 4,800
Proceeds from Sale of Property Held-for-sale	0	3,227	$ 0
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	4,027	4,027
Building and improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	95,518	93,886
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	256,478	243,810
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 16,601	$ 15,680

Leases Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
Leases Lease Cost (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Straight-line lease cost	$ 7,720	$ 7,255	$ 7,780
Operating Lease, Impairment Loss	0	0	312
Operating Lease, Expense	7,720	7,255	8,092
Depreciation	389	355	238
Interest on lease liabilities	30	33	27
Total finance lease cost	419	388	265
Total lease cost	$ 8,139	$ 7,643	$ 8,357

Leases Supplementary Balance Sheet Information (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Other assets	$ 19,425	$ 21,659
Other current liabilities	7,162	7,469
Other long-term liabilities	12,726	14,756
Total operating lease liabilities	19,888	22,225
Property, plant and equipment, gross	1,984	1,762
Accumulated depreciation	(1,145)	(825)
Property, plant and equipment, net	839	937
Current portion of long-term debt	324	197
Long-term debt	240	390
Total finance lease liabilities	$ 564	$ 587
Weighted Average Remaining Lease Term [Abstract]
Operating leases	3 years 10 months 24 days	3 years 9 months 3 days
Finance leases	3 years 18 days	3 years 2 months 19 days
Leases Weighted Average Discount Rate [Abstract]
Operating leases	5.02%	5.00%
Finance leases	4.47%	4.93%
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities	Other current liabilities
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other long-term liabilities	Other long-term liabilities
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Current portion of long-term debt	Current portion of long-term debt
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term debt	Long-term debt
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment, net	Property, plant and equipment, net

Leases Supplementary Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 7,791	$ 7,535	$ 8,459
Financing cash flows from finance leases	287	373	380
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	4,704	4,242	12,800
Finance leases	$ 305	$ 76	$ 563

Leases Maturities of Operating and Financing Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Operating Lease
2022	$ 7,162
2023	5,830
2024	4,555
2025	1,637
2026	795
Thereafter	2,174
Total lease payments	22,153
Less imputed interest	(2,265)
Total lease liabilities	19,888	$ 22,225
Finance Lease
2022	324
2023	188
2024	62
2025	8
2026	5
Thereafter	1
Total lease payments	588
Less imputed interest	(24)
Total lease liabilities	564	$ 587
Lessee, Operating Lease, Lease Not yet Commenced, Fair Value	$ 100

Goodwill and Other Intangible Assets (Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill [Roll Forward]
Goodwill beginning balance	$ 618,440	$ 618,042
Goodwill, Purchase Accounting Adjustments	0	(1,009)
Foreign currency translation	(912)	1,407
Goodwill ending balance	617,528	618,440
Accumulated goodwill impairment loss	$ 107,000	$ 107,000

Goodwill and Other Intangible Assets (Intangible Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Intangible assets, gross carrying amount	$ 761,368	$ 758,679
Intangible assets, accumulated amortization	(290,319)	(257,142)
Amortization of Intangible Assets	33,300	34,200	$ 32,300
Future amortization expense [Abstract]
2022	32,397
2023	31,665
2024	30,947
2025	31,140
2026	30,651
Expense [Member]
Future amortization expense [Abstract]
2022	26,397
2023	25,665
2024	24,947
2025	25,140
2026	24,651
Reduction of Revenue [Member]
Future amortization expense [Abstract]
2022	6,000
2023	6,000
2024	6,000
2025	6,000
2026	6,000
Trademarks and Trade Names [Member]
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Unamortized intangible assets, gross carrying amount	86,544	86,544
Customer and Distributor Relationships [Member]
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, gross carrying amount	342,452	342,639
Intangible assets, accumulated amortization	(152,934)	(134,555)
Sales representation, marketing and promotional rights [Member]
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, gross carrying amount	149,376	149,376
Intangible assets, accumulated amortization	(60,000)	(54,000)
Patents and Other Intangible Assets [Member]
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, gross carrying amount	76,392	73,516
Intangible assets, accumulated amortization	(50,890)	(48,882)
Technology-Based Intangible Assets [Member]
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, gross carrying amount	106,604	106,604
Intangible assets, accumulated amortization	$ (26,495)	$ (19,705)
Weighted Average [Member]
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	22 years
Weighted Average [Member] \| Customer and Distributor Relationships [Member]
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	24 years
Weighted Average [Member] \| Sales representation, marketing and promotional rights [Member]
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	25 years
Weighted Average [Member] \| Patents and Other Intangible Assets [Member]
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	16 years
Weighted Average [Member] \| Technology-Based Intangible Assets [Member]
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	16 years

Long Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Jan. 29, 2019
Debt Instrument [Line Items]
Long-term Debt and Lease Obligation, Including Current Maturities	$ 684,656	$ 753,636
Current portion of long-term debt	12,249	18,415
Financing leases	564	587
Long-term debt	672,407	735,221
Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Total long-term debt	140,000	207,000
Term Loan Facility [Member]
Debt Instrument [Line Items]
Total long-term debt	226,196	240,145
Unamortized Debt Issuance Expense	1,373	1,668
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible Debt	317,896	305,904
Unamortized Debt Issuance Expense	3,700	5,475
Debt Instrument, Unamortized Discount	$ 23,404	$ 33,620
2.625 Percent Convertible Notes Due 2024 [Member] \| Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			2.625%

Long Term Debt (Narrative) (Details)		12 Months Ended
Long Term Debt (Narrative) (Details)	Jan. 29, 2019 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jul. 16, 2021 USD ($)
Debt Instrument [Line Items]
Amortization of Debt Discount		$ 10,217,000	$ 9,692,000	$ 8,302,000
Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Long-term debt outstanding		140,000,000	207,000,000
Line of credit facility, available borrowing capacity		442,500,000
Revolving Line of Credit [Member] \| Amended and Restated Senior Credit Agreement [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity					$ 585,000,000
Letters of Credit [Member]
Debt Instrument [Line Items]
Letters of credit outstanding		2,500,000
Convertible Notes Payable [Member] \| 2.625 Percent Convertible Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 345,000,000
Effective Interest Rate (percent)	6.14%
Interest Expense, Debt		9,100,000	9,100,000	8,400,000
Debt Instrument, Convertible, Gross Amount of Equity Component	$ 51,600,000
Debt Instrument, Interest Rate, Stated Percentage	2.625%
Debt Instrument, Convertible, Carrying Amount of Equity Component	$ 39,100,000
Amortization of Debt Discount		10,200,000	9,700,000	$ 8,300,000
Debt Instrument, Convertible, Conversion Ratio	11.2608
Debt Instrument, Convertible, Conversion Price \| $ / shares	$ 88.80
Debt Instrument, Fair Value Disclosure		$ 576,000,000
Convertible Notes Payable [Member] \| 2.625 Percent Convertible Notes Due 2024 [Member] \| Warrant
Debt Instrument [Line Items]
Option Indexed to Issuer's Equity, Strike Price \| $ / shares	$ 114.92
Long-term Debt [Member] \| Amended and Restated Senior Credit Agreement [Member]
Debt Instrument [Line Items]
Effective Interest Rate (percent)		1.625%
LIBOR Interest Rate Floor		0.125%
Long-term Debt [Member] \| Amended and Restated Senior Credit Agreement [Member] \| Fed Funds Effective Rate Overnight Index Swap Rate [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Commitment Fee Percentage		0.50%
Long-term Debt [Member] \| Amended and Restated Senior Credit Agreement [Member] \| Adjusted LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate (percent)		1.00%
Term Loan Facility [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross		$ 227,600,000
Long-term debt outstanding		$ 226,196,000	$ 240,145,000
Term Loan Facility [Member] \| Amended and Restated Senior Credit Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount					$ 233,500,000
London Interbank Offered Rate (LIBOR) [Member] \| Long-term Debt [Member] \| Amended and Restated Senior Credit Agreement [Member]
Debt Instrument [Line Items]
Basis spread on variable rate (percent)		1.50%
Call Option [Member] \| Convertible Notes Payable [Member] \| 2.625 Percent Convertible Notes Due 2024 [Member]
Debt Instrument [Line Items]
Hedge and warrant transactions, net cash paid	$ 21,000,000

Long Term Debt (Maturities of Long-term Debt) (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Scheduled maturities of long-term debt outstanding [Abstract]
2022	$ 11,925
2023	14,906
2024	365,869
2025	23,850
2026	$ 296,019

Income Taxes (Provision for Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current tax expense:
Current Federal Tax Expense (Benefit)	$ (97)	$ (729)	$ 96
Current State and Local Tax Expense (Benefit)	609	86	444
Current Foreign Tax Expense (Benefit)	7,046	6,963	8,375
Current income tax expense (benefit)	7,558	6,320	8,915
Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]
Deferred Federal Income Tax Expense (Benefit)	3,466	(12,253)	(3,970)
Deferred State and Local Income Tax Expense (Benefit)	1,449	(1,173)	(938)
Deferred Foreign Income Tax Expense (Benefit)	(1,910)	(808)	(1,402)
Deferred income tax expense (benefit):	3,005	(14,234)	(6,310)
Provision (benefit) for income taxes	$ 10,563	$ (7,914)	$ 2,605

Income Taxes (Effective Income Tax Rate Reconciliation) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]
Tax provision at statutory rate based on income before income taxes (percent)	21.00%	21.00%	21.00%
Stock-based compensation (percent)	(9.40%)	(267.70%)	(15.40%)
Federal research credit (percent)	(2.30%)	(124.20%)	(4.00%)
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	(2.20%)	49.70%	1.90%
Effective Income Tax Rate Reconciliation, US tax on worldwide earnings at different rates, Percent	(0.40%)	(123.70%)	7.90%
Settlement of taxing authority examinations (percent)	0.00%	(122.90%)	(7.70%)
Effective Income Tax Rate Reconciliation, Tax treaty protocols, Percent	0.00%	0.00%	(2.90%)
Non deductible/non-taxable items (percent)	0.80%	28.60%	2.80%
Foreign income taxes (percent)	3.10%	79.90%	4.50%
State income taxes, net of federal tax benefit (percent)	3.70%	(24.50%)	0.30%
Other, net (percent)	0.10%	(10.10%)	(0.10%)
Effective income tax rate, continuing operations (percent)	14.40%	(493.90%)	8.30%

Income Taxes (Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Components of Deferred Tax Assets [Abstract]
Inventory	$ 4,694	$ 4,649
Net operating losses	18,383	22,197
Capitalized research and development	4,173	5,187
Deferred compensation	2,563	2,240
Accounts receivable	3,147	2,784
Compensation and benefits	6,583	7,540
Accrued pension	3,930	5,348
Research and development credit	15,542	13,540
Convertible notes hedge	4,869	6,999
Deferred Tax Assets, Lease Liabilities	3,573	4,452
Other	5,741	6,793
Less: valuation allowances	(786)	(2,721)
Deferred Tax Assets, Net of Valuation Allowance	72,412	79,008
Components of Deferred Tax Liabilities [Abstract]
Goodwill and intangible assets	106,065	104,119
Depreciation	2,546	2,512
State taxes	11,833	9,614
Unremitted foreign earnings	2,449	2,423
Convertible notes debt discount	4,915	7,060
Deferred Tax Liabilities, Leasing Arrangements	3,484	4,313
Deferred tax liabilities	131,292	130,041
Net liability	$ (58,880)	$ (51,033)

Income Taxes (Income Before Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Undistributed Earnings of Foreign Subsidiaries	$ 20,300
Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries	900
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]
U.S. income	45,260	$ (16,026)	$ 5,332
Foreign income	27,845	17,629	25,893
Income before income taxes	$ 73,105	$ 1,603	$ 31,225

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Income Taxes (Tax Credit Carryforwards) (Details) - Federal [Member] $ in Millions	Dec. 31, 2021 USD ($)
Tax Credit Carryforward [Line Items]
Operating Loss Carryforwards, After Tax Effects	$ 15.7
Research and Development Credit [Member]
Tax Credit Carryforward [Line Items]
Tax Credit Carryforwards, After Tax Effects, Amount	$ 15.5

Income Taxes (Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Unrecognized Tax Benefits [Roll Forward]
Balance as of January 1	$ 200	$ 2,170	$ 3,073
Increases for positions taken in current periods	0	0	1,650
Decreases in unrecorded tax positions related to settlement with the taxing authorities	0	(1,970)	(2,404)
Decreases in unrecorded tax positions related to lapse of statute of limitations	0	0	(149)
Balance as of December 31	$ 200	$ 200	$ 2,170

Shareholders' Equity (Details)			12 Months Ended
Shareholders' Equity (Details)	Oct. 28, 2013 $ / shares	Feb. 29, 2012 $ / shares	Dec. 31, 2021 USD ($) plans $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividends per share of common stock (in dollars per share) \| $ / shares	$ 0.20	$ 0.15	$ 0.80	$ 0.80	$ 0.80
Dividends payable			$ 5,874,000	$ 5,775,000	$ 5,684,000
Preferred stock, shares authorized (in shares) \| shares			500,000	500,000
Preferred stock, par value (in dollars per per share) \| $ / shares			$ 0.01	$ 0.01
Shares authorized under repurchase program			$ 200,000,000
Total stock repurchased under plan, shares \| shares			6,100,000
Total stock repurchased under plan, value			$ 162,600,000
Remaining authorized repurchase amount			$ 37,400,000
Number of shares reserved for share-based compensation plans \| shares			6,700,000
Number of share-based compensation plans \| plans			2
Number of shares available for grant \| shares			3,400,000
Stock-based compensation			$ 16,335,000	$ 13,111,000	11,779,000
Tax benefit from stock-based compensation			3,900,000	3,200,000	2,800,000
Proceeds from stock options exercised			$ 19,600,000	$ 13,700,000	$ 7,700,000
Stock Options and Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period from date of grant (in years)			10 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)			4 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)			5 years

Shareholders' Equity (Awards) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 45.4
Weighted average period costs expected to be recognized (in years)	3 years 6 months
Stock Options and Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value of Stock options & SARs (in dollars per share)	$ 42.47	$ 22.62	$ 20.59
Expected stock price volatility (percent)	39.27%	26.89%	26.59%
Risk-free interest rate (percent)	0.81%	0.89%	2.58%
Expected annual dividend yield (percent)	0.64%	0.82%	1.08%
Expected term of option & SARs (in years)	5 years 6 months	5 years 6 months	5 years 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares outstanding, Beginning Balance	3,336
Number of shares, Granted	701
Number of shares, Forfeited	(177)
Number of shares, Exercised	(596)
Number of shares outstanding, Ending Balance	3,264	3,336
Number of shares, Exercisable	1,284
Number of shares, Stock options & SARs expected to vest	1,980
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted average exercise price, Beginning Balance (in dollars per share)	$ 66.76
Weighted average exercise price, Granted (in dollars per share)	123.21
Weighted average exercise price, Forfeited (in dollars per share)	82.35
Weighted average exercise price, Exercised (in dollars per share)	51.59
Weighted average exercise price, Ending Balance (in dollars per share)	80.79	$ 66.76
Exercisable, Weighted Average Exercise Price (in dollars per share)	59.40
Stock options & SARs expected to vest, Weighted Average Exercise Price (in dollars per share)	$ 94.67
Weighted average remaining contractual term, options outstanding (in years)	7 years
Weighted average remaining contractual term, options exercisable (in years)	5 years 6 months
Aggregate intrinsic value, options outstanding	$ 199.0
Aggregate intrinsic value, options exercisable	105.8
Aggregate intrinsic value	$ 49.2	$ 26.6	$ 17.0
Restricted Stock Units (RSUs) and Performance Share Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of shares outstanding, Beginning Balance	61
Number of shares, Granted	21
Number of shares, Vested	(30)
Number of shares, Forfeited	(1)
Number of shares outstanding, Ending Balance	51	61
Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, Beginning Balance (in dollars per share)	$ 77.03
Weighted average grant date fair value, Granted (in dollars per share)	129.94	$ 85.45	$ 78.64
Weighted average grant date fair value, Vested (in dollars per share)	73.11
Weighted average grant date fair value, Forfeited (in dollars per share)	55.96
Weighted average grant date fair value, Ending Balance (in dollars per share)	$ 101.55	$ 77.03
Total fair value of shares vested	$ 2.2	$ 6.2	$ 2.8

Shareholders' Equity (Employee Plan) (Details)	12 Months Ended
Shareholders' Equity (Employee Plan) (Details)	Dec. 31, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for share-based compensation plans	6,700,000
Employee Plan [Member] \| Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for share-based compensation plans	1,000,000
Minimum percent of salary employees can invest	1.00%
Maximum percent of salary employees can invest	10.00%
Purchase prices percent of fair market value	95.00%
Number of shares issued under Plan	13,024

Revenues (Details) - USD ($) $ in Thousands	12 Months Ended
Revenues (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Net Sales	$ 1,010,635	$ 862,459	$ 955,097
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Net Sales	966,207	824,465	916,206
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Net Sales	44,428	37,994	38,891
Orthopedic Surgery [Member]
Disaggregation of Revenue [Line Items]
Net Sales	438,424	374,705	463,322
Orthopedic Surgery [Member] \| Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Net Sales	398,963	340,318	426,893
Orthopedic Surgery [Member] \| Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Net Sales	39,461	34,387	36,429
General Surgery [Member]
Disaggregation of Revenue [Line Items]
Net Sales	572,211	487,754	491,775
General Surgery [Member] \| Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Net Sales	567,244	484,147	489,313
General Surgery [Member] \| Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Net Sales	$ 4,967	$ 3,607	$ 2,462

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Revenues Revenue from Contracts with Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Contract with Customer, Liability, Revenue Recognized	$ 10,300	$ 9,300	$ 6,800
Contract with Customer, Liability	$ 16,760	$ 13,666

Business Segments and Geographic Areas (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) Customers	Dec. 31, 2020 USD ($) Customers	Dec. 31, 2019 USD ($) Customers
Segment Reporting Information [Line Items]
Net Sales	$ 1,010,635	$ 862,459	$ 955,097
Number of customer representing over 10% of consolidated net sales \| Customers	0	0	0
United States [Member]
Segment Reporting Information [Line Items]
Net Sales	$ 552,533	$ 482,064	$ 516,665
Americas (excluding the United States) [Member]
Segment Reporting Information [Line Items]
Net Sales	97,189	78,714	95,273
EMEA [Member]
Segment Reporting Information [Line Items]
Net Sales	189,695	161,084	182,549
Asia Pacific [Member]
Segment Reporting Information [Line Items]
Net Sales	171,218	140,597	160,610
Orthopedic Surgery [Member]
Segment Reporting Information [Line Items]
Net Sales	438,424	374,705	463,322
Orthopedic Surgery [Member] \| United States [Member]
Segment Reporting Information [Line Items]
Net Sales	158,553	139,715	179,419
Orthopedic Surgery [Member] \| Americas (excluding the United States) [Member]
Segment Reporting Information [Line Items]
Net Sales	63,824	50,356	64,269
Orthopedic Surgery [Member] \| EMEA [Member]
Segment Reporting Information [Line Items]
Net Sales	108,457	90,998	118,301
Orthopedic Surgery [Member] \| Asia Pacific [Member]
Segment Reporting Information [Line Items]
Net Sales	107,590	93,636	101,333
General Surgery [Member]
Segment Reporting Information [Line Items]
Net Sales	572,211	487,754	491,775
General Surgery [Member] \| United States [Member]
Segment Reporting Information [Line Items]
Net Sales	393,980	342,349	337,246
General Surgery [Member] \| Americas (excluding the United States) [Member]
Segment Reporting Information [Line Items]
Net Sales	33,365	28,358	31,004
General Surgery [Member] \| EMEA [Member]
Segment Reporting Information [Line Items]
Net Sales	81,238	70,086	64,248
General Surgery [Member] \| Asia Pacific [Member]
Segment Reporting Information [Line Items]
Net Sales	$ 63,628	$ 46,961	$ 59,277

- Definition

+ References

+ Details

Employee Benefit Plans (Defined Contribution Plan) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee Savings Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer contributions	$ 9.2	$ 8.9	$ 9.1

Employee Benefit Plans (Employee Benefit Reconciliation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Service cost	$ 991	$ 717	$ 1,010
Interest cost	1,803	2,555	3,130
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	76,940
Fair value of plan assets at end of year	79,404	76,940
Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)	(5,700)
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Accumulated Benefit Obligation	95,508	101,242
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Projected benefit obligation at beginning of year	101,242	92,052
Service cost	991	717
Interest cost	1,803	2,555
Actuarial loss (gain)	(3,427)	10,963
Defined Benefit Plan, Benefit Obligation, Benefits Paid	(2,703)	(1,933)
Settlement	(2,398)	(3,112)
Projected benefit obligation at end of year	95,508	101,242	92,052
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	76,940	75,321
Actual gain (loss) on plan assets	7,565	6,664
Defined Benefit Plan, Plan Assets, Benefits Paid	(2,703)	(1,933)
Settlement	(2,398)	(3,112)
Fair value of plan assets at end of year	79,404	76,940	$ 75,321
Funded status	$ (16,104)	$ (24,302)

Employee Benefit Plans (Amounts Recognized in Balance Sheet) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Liability, Defined Benefit Plan, Noncurrent	$ (16,104)	$ (24,302)
Accumulated other comprehensive loss	$ (39,122)	$ (48,285)

Employee Benefit Plans (Actuarial Assumptions) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	2.81%	2.44%
Defined Benefit Plan, Assumptions Used Calculating Net Period Benefit Cost, Benefit Obligation, Discount Rate	2.44%	3.33%	4.37%
Effective rate for interest on benefit obligation (percent)	1.83%	2.88%	4.01%
Expected return on plan assets (percent)	7.00%	7.00%	7.50%
Cumulative Gains and Losses Amortization Period Limit	12 years

Employee Benefit Plans (Other Changes in Plan Assets and Benefit Obligations) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Current year actuarial loss	$ 5,836	$ (9,320)
Amortization of actuarial loss	3,327	2,821
Total recognized in other comprehensive loss	$ 9,163	$ (6,499)

Employee Benefit Plans (Net Periodic Pension Cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Defined Benefit Plan, Non-Service Cost		$ 400	$ 1,300
Service cost	$ 991	717	1,010
Interest cost on projected benefit obligation	1,803	2,555	3,130
Expected return on plan assets	(5,155)	(5,021)	(4,725)
Amortization of loss	3,327	2,821	2,881
Net periodic pension cost	$ 966	$ 1,072	$ 2,296

Employee Benefit Plans (Allocation of Pension Plan Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Percentage of pension plan assets	100.00%	100.00%
Target allocation (percent)	100.00%
Number of CONMED shares in Plan	27,562
Fair value of CONMED shares in Plan	$ 3.9
Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Percentage of pension plan assets	73.00%	76.00%
Target allocation (percent)	75.00%
Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Percentage of pension plan assets	27.00%	24.00%
Target allocation (percent)	25.00%

Employee Benefit Plans (Fair Value of Plan Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 79,404	$ 76,940
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	30,039	27,033
Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	49,365	49,907
Common Stock [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	9,767	9,185
Fixed Income Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	20,272	17,848
Money Market Funds [Member] \| Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,098	915
Mututal Funds [Member] \| Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 48,267	$ 48,992

- Definition

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

+ References + Details

Employee Benefit Plans (Expected Future Employee Service) (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Retirement Benefits [Abstract]
2022	$ 6,427
2023	5,801
2024	5,627
2025	5,890
2026	6,026
2027-2031	$ 26,543

Legal Matters and Contingencies (Details) - USD ($) $ in Millions	Jan. 18, 2017	Dec. 31, 2021
Loss Contingencies [Line Items]
Product liability insurance, amount per incident		$ 35.0
Product liability insurance, aggregate annual amount		$ 35.0
Pending Litigation [Member] \| EndoDynamix, Inc. [Member] \| Liquidated Damages [Member]
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 12.7
Pending Litigation [Member] \| EndoDynamix, Inc. [Member] \| Additional Damages [Member]
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 24.8

Acquisition and Other Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Acquisition and Other Expense [Line Items]
Other expense	$ 1,127	$ 355	$ 5,188
Debt Instrument, Financing Costs Expensed			3,600
Loss on early extinguishment of debt	899	0	300
Cost of Sales [Member]
Acquisition and Other Expense [Line Items]
Plant underutilization cost	0	6,586	0
Manufacturing consolidation costs	0	3,993	2,858
Acquisition and integration costs	0	2,820	1,335
Product rationalization costs - inventory	0	2,169	0
Restructuring Charges	0	1,087	0
Acquisition and other expense	0	16,655	4,193
Selling and Administrative Expenses [Member]
Acquisition and Other Expense [Line Items]
Acquisition and integration costs	0	1,192	13,066
Restructuring And Related Costs	414	4,782	0
Product rationalization costs - field inventory	0	2,095	0
Acquisition and other expense	414	8,069	13,066
Selling and Administrative Expenses [Member] \| Special Termination Benefits [Member]
Acquisition and Other Expense [Line Items]
Restructuring And Related Costs		900
Selling and Administrative Expenses [Member] \| Contract Termination [Member]
Acquisition and Other Expense [Line Items]
Restructuring And Related Costs		3,800
Other Expense [Member]
Acquisition and Other Expense [Line Items]
Other expense	$ 1,127	$ 0	$ 3,904

Guarantees (Details) - USD ($) $ in Thousands	12 Months Ended
Guarantees (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Guarantees [Abstract]
Standard warranty period (in years)	1 year
Movement in Standard Product Warranty Accrual [Roll Forward]
Beginning balance	$ 1,826	$ 2,186	$ 1,585
Provision for warranties	1,458	783	1,699
Claims made	(940)	(1,143)	(1,098)
Ending balance	2,344	1,826	2,186
Extended Product Warranty Disclosure [Abstract]
Product Warranty Expense	$ 6,800	$ 6,100	$ 5,300

Fair Value Measurement Amounts Recorded In and Reclassified From AOCI (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Revenues	$ 1,010,635	$ 862,459	$ 955,097
Cost of sales	442,599	402,159	430,382
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax	8,650	(7,111)	3,871
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax	2,090	(1,718)	935
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	6,560	(5,393)	2,936
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	(4,010)	1,378	8,607
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax	(969)	333	2,079
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	(3,041)	1,045	6,528
Revenues [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	(5,421)	1,997	7,969
Cost of Sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	$ 1,411	$ (619)	$ 638

Fair Value Measurement (Foreign Currency Forward Contracts) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Derivative [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax	$ (1,832)	$ 646	$ (653)
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Asset Fair Value	5,451	1,548
Liabilities Fair Value	(771)	(9,511)
Net Fair Value	4,680	(7,963)
Foreign Exchange Forward [Member]
Derivative [Line Items]
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	(451)	(2,269)	$ (573)
Derivatives designated as hedging instruments: \| Foreign Exchange Forward [Member]
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Asset Fair Value	5,413	1,523
Liabilities Fair Value	(591)	(9,361)
Net Fair Value	4,822	(7,838)
Derivatives designated as hedging instruments: \| Foreign Exchange Forward [Member] \| Prepaid expenses and other current assets
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Asset Fair Value	5,331
Liabilities Fair Value	(430)
Net Fair Value	4,901
Derivatives designated as hedging instruments: \| Foreign Exchange Forward [Member] \| Other long-term liabilities
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Asset Fair Value	82	23
Liabilities Fair Value	(161)	(535)
Net Fair Value	(79)	(512)
Derivatives designated as hedging instruments: \| Foreign Exchange Forward [Member] \| Other current liabilities
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Asset Fair Value		1,500
Liabilities Fair Value		(8,826)
Net Fair Value		(7,326)
Not Designated as Hedging Instrument [Member] \| Foreign Exchange Forward [Member]
Derivative [Line Items]
Derivative, Notional Amount	38,897	42,380
Not Designated as Hedging Instrument [Member] \| Foreign Exchange Forward [Member] \| Other current liabilities
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Asset Fair Value	38	25
Liabilities Fair Value	(180)	(150)
Net Fair Value	$ (142)	(125)
Not Designated as Hedging Instrument [Member] \| Foreign Exchange Forward [Member]
Derivative [Line Items]
Maximum Length of Time Hedged in Cash Flow Hedge	1 month
Cash Flow Hedging [Member] \| Foreign Exchange Forward [Member]
Derivative [Line Items]
Maximum Length of Time Hedged in Cash Flow Hedge	2 years
Derivative, Notional Amount	$ 172,894	$ 154,504
Unrealized gain (loss) on cash flow hedges in accumulated other comprehensive income (loss) expected to be recognized in next fiscal year	$ 3,700

New Accounting Pronouncements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt		$ 672,407	$ 735,221
Paid-in capital		396,771	382,628
Deferred income taxes		68,537	57,875
Interest expense		35,485	44,052	$ 42,701
Retained earnings		$ 496,605	$ 457,417
Accounting Standards Update 2020-06 \| Forecast
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt					$ 22,600
Paid-in capital					(37,900)
Deferred income taxes					(5,500)
Interest expense	$ (10,400)
Retained earnings					$ 20,800

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References + Details

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Allowance for Bad Debts [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 3,876	$ 2,786	$ 2,660
Charged to costs and expenses	2,305	1,611	852
Deductions	(1,653)	(521)	(726)
Balance at end of period	4,528	3,876	2,786
Sales Returns and Allowances [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	3,684	3,667	3,246
Charged to costs and expenses	1,261	384	518
Deductions	(504)	(367)	(97)
Balance at end of period	4,441	3,684	3,667
Deferred Tax Asset Valuation Allowance [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	2,721	1,732	1,159
Charged to costs and expenses	621	989	573
Deductions	(2,556)	0	0
Balance at end of period	$ 786	$ 2,721	$ 1,732